Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis

Emily Shepherd1,2*, Rehana A. Salam1,2, Deepak Manhas3, Anne Synnes3, Philippa Middleton1,2, Maria Makrides2, Caroline A. Crowther1,4

1 Robinson Research Institute, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia, 2 South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia, 3 University of British Columbia, Vancouver, British Columbia, Canada, 4 Liggins Institute, University of Auckland, Auckland, New Zealand

* emily.shepherd@adelaide.edu.au

Abstract

Background

There is widespread, increasing use of magnesium sulphate in obstetric practice for pre-eclampsia, eclampsia, and preterm fetal neuroprotection; benefit for preventing preterm labour and birth (tocolysis) is unproven. We conducted a systematic review and meta-analysis to assess whether antenatal magnesium sulphate is associated with unintended adverse neonatal outcomes.

Methods and findings

CINAHL, Cochrane Library, LILACS, MEDLINE, Embase, TOXLINE, and Web of Science, were searched (inceptions to 3 September 2019). Randomised, quasi-randomised, and non-randomised trials, cohort and case-control studies, and case reports assessing antenatal magnesium sulphate for pre-eclampsia, eclampsia, fetal neuroprotection, or tocolysis, compared with placebo/no treatment or a different magnesium sulphate regimen, were included. The primary outcome was perinatal death. Secondary outcomes included pre-specified and non-pre-specified adverse neonatal outcomes. Two reviewers screened 5,890 articles, extracted data, and assessed risk of bias following Cochrane Handbook and RTI Item Bank guidance. For randomised trials, pooled risk ratios (RRs) or mean differences, with 95% confidence intervals (CIs), were calculated using fixed- or random-effects meta-analysis. Non-randomised data were tabulated and narratively summarised. We included 197 studies (40 randomised trials, 138 non-randomised studies, and 19 case reports), of mixed quality. The 40 trials (randomising 19,265 women and their babies) were conducted from 1987 to 2018 across high- (16 trials) and low/middle-income countries (23 trials) (1 mixed). Indications included pre-eclampsia/eclampsia (24 trials), fetal neuroprotection (7 trials), and tocolysis (9 trials); 18 trials compared magnesium sulphate with placebo/no treatment, and 22 compared different regimens. For perinatal death, no clear difference in randomised trials was observed between magnesium sulphate and placebo/no treatment.
(RR 1.01; 95% CI 0.92 to 1.10; 8 trials, 13,654 babies), nor between regimens. Eleven of 138 non-randomised studies reported on perinatal death. Only 1 cohort (127 babies; moderate to high risk of bias) observed an increased risk of perinatal death with >48 versus ≤48 grams magnesium sulphate exposure for tocolysis. No clear secondary adverse neonatal outcomes were observed in randomised trials, and a very limited number of possible adverse outcomes warranting further consideration were identified in non-randomised studies. Where non-randomised studies observed possible harms, often no or few confounders were controlled for (moderate to high risk of bias), samples were small (200 babies or fewer), and/or results were from subgroup analyses. Limitations include missing data for important outcomes across most studies, heterogeneity of included studies, and inclusion of published data only.

**Conclusions**

Our findings do not support clear associations between antenatal magnesium sulphate for beneficial indications and adverse neonatal outcomes. Further large, high-quality studies (prospective cohorts or individual participant data meta-analyses) assessing specific outcomes, or the impact of regimen, pregnancy, or birth characteristics on these outcomes, would further inform safety recommendations. PROSPERO: CRD42013004451.

**Author summary**

**Why was this study done?**

- Magnesium sulphate is widely used in pregnancy, considered effective for maternal neuroprotection in pre-eclampsia/eclampsia and for fetal neuroprotection (cerebral palsy prevention) in women at risk of preterm birth, and ineffective for preventing preterm birth or labour (tocolysis).

- It is important to understand whether this treatment, when given to women in pregnancy, is associated with any unintended adverse outcomes for babies.

**What did the researchers do and find?**

- This systematic review incorporates the findings of 197 studies (including 40 randomised controlled trials) that reported on adverse outcomes for babies whose mothers were treated with magnesium sulphate in pregnancy.

- Meta-analysis of randomised controlled trials showed no clear difference in the risk of perinatal death between babies whose mothers were treated with magnesium sulphate and those whose mothers received placebo/no treatment, or between different magnesium sulphate regimens.

- No clear adverse outcomes for babies were observed in randomised trials, and a very limited number of possible adverse outcomes warranting further consideration were identified in non-randomised studies.
What do these findings mean?

• Magnesium sulphate in pregnancy, when given for the beneficial indications of maternal or fetal neuroprotection, is not associated with an increased risk of perinatal death or other adverse outcomes for babies.

• Further investigation into specific adverse outcomes, and the impact of particular treatment regimen, pregnancy, and/or birth characteristics, would further inform safety recommendations.

Introduction

Antenatal magnesium sulphate is commonly used in obstetric practice. Systematic reviews and clinical practice guidelines support its use when given for maternal neuroprotection in pre-eclampsia or eclampsia [1–3] and for neuroprotection of the fetus in women at risk of preterm birth (for cerebral palsy prevention) [4–7]. Despite continued use in some countries [8], available evidence does not support its role in preventing preterm birth in women with, or following, threatened preterm labour (for tocolysis) [7,9].

Concerns surrounding possible unintended adverse outcomes for fetuses or neonates following exposure to antenatal magnesium sulphate emerged over 50 years ago [10,11], and uncertainty persists today. While the clinical consequences of hypermagnesemia, related to increased serum concentrations, are well known and documented (such as lethargy, drowsiness, flushing, nausea, vomiting, muscle weakness, loss of deep tendon reflexes, hypotension, apnoea, coma, cardiac arrest, and, ultimately, death [12]), whether neonates are at risk of such adverse outcomes following exposure to antenatal magnesium sulphate is unclear.

We have systematically reviewed the maternal adverse effects of different antenatal magnesium sulphate regimens [13], and a further systematic review has summarised the effects specifically on fetal heart rate [14]. To our knowledge, a broad evaluation of evidence surrounding potential unintended neonatal adverse outcomes, informed by current guidance [15–17], has not previously been conducted. Implementation of this treatment may be strengthened, and its safety improved, if guidelines and recommendations for practice can be based on such knowledge.

The aim of our study, therefore, was to conduct a comprehensive systematic review to assess whether antenatal magnesium sulphate is associated with perinatal death and other unintended adverse neonatal outcomes.

Methods

We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline; the relevant checklist is provided in S1 PRISMA Checklist. Prior to conduct, this systematic review was registered with PROSPERO (International Prospective Register of Systematic Reviews; CRD42013004451) [18]. The Australian Cerebral Palsy Alliance Research Foundation–funded review protocol is available in S1 Text. Ethical approval was not required.
Search strategy

Comprehensive searches of the bibliographic databases CINAHL, Cochrane Library, LILACS, MEDLINE, Embase, TOXLINE, and Web of Science were undertaken from their respective inceptions to 3 September 2019, using combinations of MeSH and free text terms. The search strategies are available in S2 Text. No date or language restrictions were applied; however, because of logistical constraints, for non-English papers, only those with an available English abstract or full-text translation were retrieved. The reference lists of eligible articles were checked for additional reports.

Inclusion criteria

We included randomised and quasi-randomised controlled trials as well as non-randomised controlled studies (non-randomised trials, cohort studies, and case–control studies), and case reports. We excluded cross-sectional studies and case series. We included studies available as abstracts only, along with full-text publications.

We included neonates who were exposed to antenatal magnesium sulphate, regardless of their gestational age at exposure or birth. We included studies where antenatal magnesium sulphate was given for pre-eclampsia or eclampsia, for neuroprotection of the fetus, or for tocolysis. We excluded studies where magnesium sulphate was given as an adjuvant during obstetric anaesthesia. We included intervention studies in which magnesium sulphate was compared with no treatment, placebo, or a different magnesium sulphate regimen. We included observational studies where magnesium sulphate was assessed as an 'exposure'. We excluded studies where magnesium sulphate was compared with another therapy (for example, diazepam for pre-eclampsia or eclampsia, or nifedipine for tocolysis).

We included studies that reported on adverse outcomes for neonates, however defined. The primary outcome was perinatal death. Secondary outcomes included pre-specified adverse outcomes (based on non-systematic literature review: stillbirth, neonatal death or death up to hospital discharge, low Apgar scores at 1 and 5 minutes, need for active resuscitation at birth, respiratory depression, spontaneous intestinal perforation, patent ductus arteriosus, hypotension, lethargy, hypotonia or hyporeflexia, osteopenia or bone fractures, neonatal intensive care unit admission, and duration of neonatal care unit admission), along with other non-pre-specified adverse neonatal outcomes.

Study selection

After screening all titles and abstracts, we obtained full-text articles for studies that appeared to meet the inclusion criteria. All full-text articles were assessed for inclusion. Each stage was carried out by 2 reviewers, and we resolved any discrepancies through discussion, or, if required, we consulted a third reviewer.

Data extraction and management

For included studies, data were extracted using a standardised form, including information regarding design, participants, the magnesium sulphate regimen(s), the control/comparison if applicable, neonatal adverse outcomes reported, results relevant to the review, and the risk of bias. For all randomised trials, all case reports, and 60% of non-randomised studies, extraction was carried out by 2 reviewers (for 40% of non-randomised studies, extractions were checked by a second reviewer), and we resolved discrepancies through discussion, or, if required, we consulted a third reviewer.
Assessment of risk of bias

Quality appraisal of intervention studies was undertaken utilising established guidelines provided in the Cochrane Handbook for Systematic Reviews of Interventions [19]. The quality assessment of observational studies was guided by the RTI Item Bank [20].

Data synthesis and analysis

Data analyses were undertaken by study design. Statistical analyses for randomised trials were performed using Review Manager, version 5.3 [21]. We present quantitative data from individual studies as risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, with 95% confidence intervals (CIs). For all outcomes, we carried out analyses as far as possible on an intention-to-treat basis. Pooled estimates were calculated using fixed-effects meta-analysis (Mantel-Haenszel method) where there was a sufficient quantity of data, with clinical homogeneity. Where there was substantial statistical heterogeneity (where $I^2$ was greater than 30% and either $T^2$ was greater than 0 or there was a low $P$ value [less than 0.10] in the $\chi^2$ test), summary estimates were calculated using random-effects meta-analysis. Where there were 10 or more trials in a meta-analysis, we investigated reporting biases (such as publication bias) using funnel plots, which we assessed visually.

Separate comparisons were performed for those studies assessing magnesium sulphate versus no treatment/placebo and those comparing different magnesium sulphate regimens. For our primary review outcome (perinatal death) and other mortality outcomes, we conducted subgroup analyses based on indication for use and characteristics of the magnesium sulphate loading and maintenance dose regimens, as these factors were considered likely to influence outcomes. It was not possible to conduct subgroup analyses based on other pregnancy or birth characteristics (gestational age at magnesium sulphate administration, birthweight, mode of birth, and concomitant maternal treatments) due to paucity of data. We assessed subgroup differences by interaction tests available within Review Manager, and, where applicable, we have quoted the $\chi^2$ statistic and $P$ value, and the interaction test $I^2$ value.

For observational studies (non-randomised trials, cohort studies, and case–control studies), we present effect estimates where possible as adjusted RRs or odds ratios if reported with 95% CIs, unadjusted RRs or odds ratios with 95% CIs, $P$ values only, or percentages (rates), in tabular format; we used narrative synthesis to summarise the studies. Data from case reports were grouped according to common adverse outcomes, tabulated, and summarised narratively.

Results

Study selection

The results of the search strategy, including the sources of the studies, their assessment, and final inclusion are shown in Fig 1. The database searching identified 5,890 records, and other searching identified a further 11 records. Review of the titles and abstracts and exclusion of irrelevant and duplicate records yielded 777. Of these, we excluded 572 for the documented reasons (see S3 Text for list of records excluded due to absence of an English translation). We included a total of 205 articles, relating to 197 studies. See S4 Text for references for all included studies. In the case of multiple publications from the same study, we included the report with the most relevant data as the primary reference, and only included further publications as secondary references if they provided additional relevant data.
Evidence from randomised controlled trials

Forty randomised trials were included, the characteristics of which are detailed in S1 Table, and the risk of bias assessments are summarised in Fig 2, S1 Fig, and S2 Table [22–61]. The trials assessed a range of different magnesium sulphate regimens with varying control groups, and are therefore assessed under 8 different comparisons:
1. Magnesium sulphate versus placebo or no treatment (18 trials)
2. Lower versus higher dose regimens of magnesium sulphate (8 trials)
3. Intramuscular (IM) versus intravenous (IV) maintenance dose of magnesium sulphate (5 trials)
4. Loading versus loading and maintenance dose of magnesium sulphate (5 trials)
5. Serial IV boluses versus continuous IV infusion of magnesium sulphate (1 trial)
6. Short versus standard maintenance of magnesium sulphate (1 trial)
7. Slower versus standard rate of loading dose infusion of magnesium sulphate (1 trial)
8. Weaning versus no weaning of maintenance of magnesium sulphate (1 trial)

The methodological quality of the 40 trials varied considerably. Considering selection bias, 18 trials were at low risk, reporting adequate methods for sequence generation and allocation concealment. Twelve and 8 trials received an unclear judgement for 1 and 2 of the selection bias domains, respectively. Two trials appeared to be quasi-randomised and thus were at high risk of selection bias. Twelve trials were at low risk of performance and detection bias (with blinding of participants, personnel, and outcome assessors); 21 were at high risk of both performance and detection bias (all trials of different magnesium sulphate regimens, with no reported blinding), and the remaining 7 trials had an unclear judgement for 1 or 2 of the blinding domains. The majority of trials (31) were at low risk of attrition bias for neonatal outcome data, though for 9 trials, this was unclear. Only 5 trials were at low risk of reporting bias, 1 was at high risk of reporting bias, and for the remaining 34 trials, selective reporting was unclear.

**Magnesium sulphate versus placebo or no treatment**

This comparison included 18 trials. The indication for use of magnesium sulphate in 6 trials was the prevention of eclampsia [30,32,39,43,48,61]; in 6 trials, fetal neuroprotection [28,36,45,47,51,54]; and in 6 trials, the prevention of preterm birth (tocolysis) [33–35,38,40,46].
Magnesium sulphate regimens assessed varied considerably: 4-gram IV loading dose only (2 trials), 4-gram IV loading dose and 1-gram-per-hour IV maintenance dose (4 trials), 4-gram IV loading dose and 2-gram-per-hour IV maintenance dose (4 trials), 6-gram IV loading dose and 2-gram-per-hour IV maintenance dose (6 trials), and 4-gram IV and 10-gram IM loading dose and 5-gram IM maintenance dose every 4 hours (2 trials), with duration of treatment generally ranging from 12 to 24 hours. Fourteen trials compared magnesium sulphate with a placebo, while 4 trials had a no-treatment comparison (see Table 1 and S1 Appendix for effect estimates, forest plots, and funnel plots).

No clear difference was seen between magnesium sulphate and placebo/no treatment for the primary review outcome perinatal death (RR 1.01; 95% CI 0.92 to 1.10; 8 trials, 13,654 babies; analysis 1.1), nor for stillbirth, neonatal death (no obvious asymmetry observed on visual assessment of funnel plot), death later than 28 days but before discharge, early neonatal death, or late neonatal death (Table 1; S1 Appendix). When considering indication for use, the tocolysis subgroup showed an increase in perinatal death (RR 7.99; 95% CI 1.00 to 63.49; 2 trials, 257 babies; analysis 1.1) that was not observed in the pre-eclampsia or fetal neuroprotection subgroups. The subgroup interaction test, however, did not indicate a differential effect according to treatment indication ($\chi^2 = 4.07$, $P = 0.13$, $I^2 = 50.8\%$). For the remaining mortality outcomes, subgroup interaction tests did not indicate differential treatment effects according to indication for administration (see Tables 2 and 3 for effect estimates for individual subgroups and results from subgroup interaction tests).

Babies exposed to antenatal magnesium sulphate had a 67% relative increase in the risk of having an Apgar score less than 7 at 1 minute (RR 1.67; 95% CI 1.02 to 2.73; 2 trials, 199 babies; analysis 1.7), and over 2 times the risk of need for volume expansion compared with babies not exposed (RR 2.03; 95% CI 1.01 to 4.10; 1 trial, 87 babies; analysis 1.28). A subgroup of babies born less than 32 weeks gestation exposed to antenatal magnesium sulphate had a 62% relative reduction in the risk of intracerebral echodensity, compared with babies not exposed (RR 0.38; 95% CI 0.19 to 0.79; 1 trial, 1,613 babies; analysis 1.46). While a difference in intracerebral echolucency was not observed in all babies, a 39% relative reduction was seen for babies born less than 32 weeks exposed to antenatal magnesium sulphate (RR 0.61; 95% CI 0.38 to 0.97; 1 trial, 1,613 babies; analysis 1.47.2) (Table 1; S1 Appendix).

There were no clear differences between magnesium sulphate and placebo/no treatment for all remaining secondary outcomes reported (Table 1; S1 Appendix).

### Lower versus higher dose regimens

This comparison included 8 trials, with 6 assessing magnesium sulphate for treatment of eclampsia or severe pre-eclampsia [22,23,44,52,56,59], and 2 for the prevention of preterm birth (tocolysis) [26,60]. Regimens assessed varied: lower dose regimens included a 4- to 10-gram loading dose with a 0.625- to 2-gram-per-hour maintenance dose; higher dose regimens assessed included a 4- to 14-gram loading dose with a 1.25- to 5-gram-per-hour maintenance dose (see Table 4 and S1 Appendix for effect estimates and forest plots).

No clear differences between the lower and higher dose regimens of magnesium sulphate were seen for the primary review outcome perinatal death (RR 1.01; 95% CI 0.75 to 1.36; 6 trials, 543 babies; analysis 2.1), nor for stillbirth or neonatal death (Table 4; S1 Appendix). For all mortality outcomes, subgroup interaction tests did not indicate differential treatment effects according to indication for administration of antenatal magnesium sulphate (see Table 5 for effect estimates for individual subgroups and results from subgroup interaction tests).

Babies exposed to the lower dose versus higher dose regimens of magnesium sulphate had an increased risk of neonatal intensive care unit admission (RR 1.75; 95% CI 1.06 to 2.88; 5
| Outcome | Studies | Participants | Method (I²) | RR (95% CI) |
|---|---|---|---|---|
| 1.1 Perinatal death | 8 | 13,654 | F (23%) | 1.01 (0.92, 1.10) |
| 1.2 Stillbirth | 9 | 12,340 | F (0%) | 0.99 (0.87, 1.12) |
| 1.3 Neonatal death | 11 | 12,987 | F (21%) | 1.00 (0.86, 1.17) |
| 1.4 Death > 28 days, before discharge | 5 | 10,691 | F (0%) | 0.96 (0.60, 1.53) |
| 1.5 Early neonatal death | 1 | 9,024 | F (NA) | 1.09 (0.86, 1.37) |
| 1.6 Late neonatal death | 1 | 9,024 | F (NA) | 1.54 (0.95, 2.49) |
| 1.7 Apgar score < 7 at 1 minute | 2 | 199 | F (17%) | 1.67 (1.02, 2.73) |
| 1.8 Apgar score < 7 at 5 minutes | 5 | 12,729 | F (0%) | 1.02 (0.92, 1.14) |
| 1.9 Meconium at birth | 1 | 210 | F (NA) | 1.55 (0.89, 2.72) |
| 1.10 Intubated at birth | 3 | 11,364 | F (30%) | 0.95 (0.87, 1.04) |
| 1.11 Resuscitation in the delivery room | | | | |
| 1.11.1 Any | 1 | 2,416 | F (NA) | 0.99 (0.96, 1.03) |
| 1.11.2 Oxygen bag, mask, or both | 1 | 2,416 | F (NA) | 1.07 (0.98, 1.17) |
| 1.11.3 Chest compressions | 1 | 2,416 | F (NA) | 1.11 (0.73, 1.71) |
| 1.12 Respiratory distress syndrome | 7 | 3,639 | R (46%) | 0.95 (0.79, 1.14) |
| 1.13 Transient tachypnoea of the newborn | 2 | 243 | F (0%) | 0.96 (0.52, 1.77) |
| 1.14 Surfactant | 1 | 87 | F (NA) | 0.88 (0.62, 1.24) |
| 1.15 Mechanical ventilation | 5 | 12,751 | R (63%) | 1.01 (0.94, 1.09) |
| 1.16 Non-invasive ventilation | 1 | 688 | F (NA) | 1.03 (0.93, 1.15) |
| 1.17 Oxygen required | 1 | 153 | F (NA) | 0.95 (0.67, 1.35) |
| 1.18 Chronic lung disease | 5 | 4,513 | F (0%) | 1.06 (0.96, 1.17) |
| 1.19 Apnoea and bradycardia | 2 | 841 | F (0%) | 1.23 (0.98, 1.53) |
| 1.20 Pneumothorax | 1 | 87 | F (NA) | 2.44 (0.26, 22.52) |
| 1.21 Pulmonary haemorrhage | 1 | 87 | F (NA) | 2.44 (0.52, 11.41) |
| 1.22 Necrotising enterocolitis | 8 | 4,804 | F (0%) | 1.21 (0.98, 1.51) |
| 1.23 Sepsis | 4 | 2,694 | R (31%) | 0.83 (0.54, 1.28) |
| 1.24 Hypoglycaemia on NICU admission | 1 | 34 | F (NA) | 0.63 (0.06, 6.34) |
| 1.25 Poor feeding | 1 | 90 | F (NA) | No events |
| 1.26 Patent ductus arteriosus | 3 | 2,536 | F (26%) | 0.97 (0.80, 1.17) |
| 1.27 Hypotension | 2 | 3,103 | F (22%) | 1.03 (0.89, 1.19) |
| 1.28 Volume expansion | 1 | 87 | F (NA) | 2.03 (1.01, 4.10) |
| 1.29 Mean blood pressure < 10th centile in the first 24 hours | 1 | 87 | F (NA) | 1.30 (0.67, 2.53) |
| 1.30 Superior vena cava flow < 41 ml/kg/min in the first 24 hours | 1 | 87 | F (NA) | 1.22 (0.62, 2.40) |
| 1.31 Right ventricular output < 120 ml/kg/min in the first 24 hours | 1 | 87 | F (NA) | 1.08 (0.51, 2.30) |
| 1.32 Dobutamine | 1 | 87 | F (NA) | 1.73 (0.84, 3.57) |
| 1.33 Dopamine | 1 | 87 | F (NA) | 2.17 (0.62, 7.62) |
| 1.34 Any inotrope | 1 | 87 | F (NA) | 1.54 (0.82, 2.92) |
| 1.35 Retinopathy of prematurity | 1 | 2,415 | F (NA) | 0.99 (0.85, 1.14) |
| 1.36 Generalised hypotonia | 1 | 2,415 | F (NA) | 1.03 (0.77, 1.37) |
| 1.37 Seizures | 4 | 11,397 | F (0%) | 0.78 (0.57, 1.06) |
| 1.38 Hyperbilirubinaemia | 1 | 90 | F (NA) | 2.00 (0.19, 21.28) |
| 1.39 Intraventricular haemorrhage | 10 | 4,891 | F (0%) | 0.95 (0.85, 1.06) |
| 1.40 Intraventricular haemorrhage, grade 3 or 4 | 6 | 3,769 | F (19%) | 0.81 (0.60, 1.09) |
| 1.41 Periventricular leucomalacia | 4 | 4,225 | F (0%) | 0.93 (0.68, 1.28) |
| 1.42 Any white matter injury | 1 | 665 | F (NA) | 0.87 (0.62, 1.22) |
| 1.43 Severe white matter injury | 1 | 688 | F (NA) | 0.85 (0.55, 1.32) |
| 1.44 Severe white matter injury or death | 1 | 688 | F (NA) | 0.92 (0.66, 1.28) |

(Continued)
| Outcome                                                                 | Studies | Participants | Method ($I^2$) | RR (95% CI)       |
|------------------------------------------------------------------------|---------|--------------|----------------|------------------|
| 1.45 Persistent parenchymal echogenicity                               | 1       | 8,260        | F (NA)         | 1.09 (0.66, 1.81) |
| 1.46 Echodensity in children born < 32 weeks                          | 1       | 1,613        | F (NA)         | **0.38 (0.19, 0.79)** |
| 1.47 Echolucency                                                       |         |              |                |                  |
| 1.47.1 In all children                                                | 1       | 1,776        | F (NA)         | 0.62 (0.37, 1.03) |
| 1.47.2 In children born < 32 weeks                                    | 1       | 1,613        | F (NA)         | **0.61 (0.38, 0.97)** |
| 1.48 Ventriculomegaly                                                 | 2       | 10,036       | F (0%)         | 0.98 (0.68, 1.42) |
| 1.49 Any of echodensity, echolucency, intraventricular haemorrhage, periventricular haemorrhage, or ventriculomegaly |         |              |                |                  |
| 1.49.1 In all children                                                | 1       | 1,776        | F (NA)         | 0.85 (0.69, 1.06) |
| 1.49.2 In children born < 32 weeks                                    | 1       | 1,613        | F (NA)         | 0.92 (0.78, 1.09) |
| 1.50 Composite adverse outcome                                        | 1       | 1,776        | F (NA)         | 0.62 (0.37, 1.03) |
| 1.51 NICU admission                                                   | 3       | 8,519        | F (17%)        | 1.00 (0.95, 1.06) |
| 1.52 Intensive care unit stay (days)                                  | 1       | 120          | MD, F (NA)     | 0.02 (−0.17, 0.21) |
| 1.53 Hospital stay (days)                                             | 2       | 257          | MD, R (99%)    | −2.75 (−8.92, 3.43) |
| 1.54 Special care baby unit admission > 7 days or death               | 1       | 9,024        | F (NA)         | 1.01 (0.95, 1.08) |
| 1.55 Special care baby unit admission > 7 days                        | 1       | 8,260        | F (NA)         | 1.02 (0.93, 1.11) |
| 1.56 Still in hospital at 6 weeks                                     | 1       | 9,024        | F (NA)         | 0.99 (0.06, 15.80) |

Statistically significant effect estimates in bold. Test for heterogeneity represented by $I^2$ statistic; where $I^2 > 30\%$, summary estimates were calculated using random-effects meta-analysis. CI, confidence interval; F, fixed-effects; MD, mean difference; NA, not applicable; NICU, neonatal intensive care unit; R, random-effects; RR, risk ratio.

https://doi.org/10.1371/journal.pmed.1002988.t001

| Outcome and subgroup | Studies | Participants | Method ($I^2$) | RR (95% CI)       | $\chi^2$, P value, $I^2$ |
|----------------------|---------|--------------|----------------|------------------|--------------------------|
| 1.1 Perinatal death  |         |              |                |                  |                          |
| 1.1.1 Tocolysis      | 2       | 257          | F (NA)         | **7.99 (1.00, 63.49)** | 4.07, 0.13, 50.8%         |
| 1.1.2 Pre-eclampsia  | 2       | 9,259        | F (0%)         | 1.01 (0.91, 1.13) |                          |
| 1.1.3 Fetal neuroprotection | 4    | 4,138        | F (0%)         | 0.96 (0.80, 1.15) |                          |
| 1.2 Stillbirth       |         |              |                |                  |                          |
| 1.2.1 Tocolysis      | 2       | 257          | F (NA)         | 5.70 (0.28, 116.87) | 1.45, 0.49, 0%            |
| 1.2.2 Pre-eclampsia  | 3       | 9,961        | F (8%)         | 0.99 (0.87, 1.12) |                          |
| 1.2.3 Fetal neuroprotection | 4    | 2,122        | F (0%)         | 0.85 (0.40, 1.80) |                          |
| 1.3 Neonatal death   |         |              |                |                  |                          |
| 1.3.1 Tocolysis      | 4       | 445          | R (61%)        | 0.78 (0.11, 5.67) | 0.48, 0.79, 0%            |
| 1.3.2 Pre-eclampsia  | 2       | 9,259        | R (35%)        | 1.03 (0.64, 1.65) |                          |
| 1.3.3 Fetal neuroprotection | 5    | 3,283        | R (0%)         | 0.86 (0.68, 1.08) |                          |
| 1.4 Death > 28 days, before discharge                                |         |              |                |                  |                          |
| 1.4.1 Tocolysis      | 3       | 412          | F (0%)         | 0.76 (0.19, 3.09) | 0.37, 0.83, 0%            |
| 1.4.2 Pre-eclampsia  | 1       | 9,024        | F (NA)         | 1.13 (0.55, 2.31) |                          |
| 1.4.3 Fetal neuroprotection | 1    | 1,255        | F (NA)         | 0.88 (0.44, 1.74) |                          |

Statistically significant effect estimates in bold. Test for heterogeneity represented by $I^2$ statistic; where $I^2 > 30\%$, summary estimates were calculated using random-effects meta-analysis. Result of test subgroup differences represented by $\chi^2$ statistic, P value, and $I^2$ statistic. CI, confidence interval; F, fixed-effects; NA, not applicable; R, random-effects; RR, risk ratio.

https://doi.org/10.1371/journal.pmed.1002988.t002
trials, 409 babies; analysis 2.17). On average, babies exposed to the lower dose regimen had a longer duration of stay in the neonatal intensive care unit compared with those exposed to the higher dose regimen (MD 3.10 days; 95% CI 0.78 to 5.42; 1 trial, 104 babies; analysis 2.18) (Table 4; S1 Appendix).
No clear differences were seen between the lower and higher dose regimens of magnesium sulphate for the remaining secondary outcomes reported (Table 4; S1 Appendix).

**IM versus IV maintenance dose**

This comparison included 5 trials, all assessing magnesium sulphate for the prevention or treatment of eclampsia [27,31,49,55,58]. Regimens assessed included Bhattacharjee’s regimen.
(4-gram IV loading dose; 6-gram IV maintenance dose every 8 hours), Dhaka regimen (4-gram IV and 6-gram IM loading dose; 2.5-gram IM maintenance dose every 4 hours), Pritchard’s regimen (4-gram IV and 10-gram IM loading dose; 5-gram IM maintenance dose every 4 hours), Zuspan’s regimen (4-gram IV loading dose; 1-gram IV maintenance dose every hour), and Sibai’s regimen (6-gram IV loading dose; 2-gram IV maintenance dose every hour) (all maintenance doses were for 24 hours after birth or last seizure) (see Table 6 and S1 Appendix for effect estimates and forest plots).

No clear differences were observed for
• Pritchard’s versus Zuspan’s regimen for the primary review outcome perinatal death (RR 0.94; 95% CI 0.66 to 1.32; 2 trials, 353 babies; analysis 3.1.1), nor for stillbirth or neonatal death;
• Pritchard’s versus Sibai’s regimen for the primary review outcome perinatal death (RR 0.90; 95% CI 0.53 to 1.53; 1 trial, 115 babies; analysis 3.1.2), nor for stillbirth or neonatal death;
• Pritchard’s versus Bhattacharjee’s regimen for the primary review outcome perinatal death (RR 1.28; 95% CI 0.61 to 2.65; 1 trial, 107 babies; analysis 3.1.3), nor for stillbirth or neonatal death;
• Dhaka versus Zuspan’s regimen for the primary review outcome perinatal death (RR 0.57; 95% CI 0.16 to 2.08; 1 trial, 41 babies; analysis 3.1.4), nor for stillbirth or neonatal death (Table 6; S1 Appendix).

No clear differences were observed for Pritchard’s versus Zuspan’s regimen, Pritchard’s versus Sibai’s regimen, or Dhaka versus Zuspan’s regimen for the remaining secondary outcomes reported (Table 6; S1 Appendix).

Loading dose versus loading and maintenance doses
This comparison included 5 trials, all assessing magnesium sulphate for the prevention or treatment of eclampsia [25,41,50,53,57]. Trials compared a cumulative 8-, 10-, or 14-gram loading dose (4 grams IV and 4 to 10 grams IM) with Dhaka or Pritchard’s regimen (see descriptions above; and see Table 6 and S1 Appendix for effect estimates and forest plots).

No clear differences for loading dose only versus loading and maintenance dose regimens were seen for the primary review outcome perinatal death (average RR 0.94; 95% CI 0.33 to 2.72; 3 trials, 632 babies; analysis 4.1), nor for stillbirth, neonatal death, or neonatal death at less than 7 days (Table 6; S1 Appendix).

No clear differences for loading dose only versus loading and maintenance dose regimens were seen for the remaining secondary outcomes reported (Table 6; S1 Appendix).

Serial IV boluses versus continuous IV maintenance dose
This comparison included 1 trial, assessing magnesium sulphate for the treatment of severe pre-eclampsia, and compared a serial intravenous bolus regimen (6-gram IV loading dose, and 2-gram IV bolus over 10 minutes every 2 hours as maintenance) with a continuous infusion (4-gram IV loading dose, and 1-gram-per-hour continuous IV maintenance dose) [37] (see Table 6 and S1 Appendix for effect estimates and forest plots).

No clear differences between the serial bolus and continuous infusion regimens were seen for the primary review outcome perinatal death (RR 0.44; 95% CI 0.08 to 2.34; 1 trial, 197 babies; analysis 5.1), nor for stillbirth or neonatal death (Table 6; S1 Appendix).

No clear differences between the serial bolus and continuous infusion regimens were seen for the remaining secondary outcomes reported (Table 6; S1 Appendix).
### Table 6. Adverse outcome estimates from randomised controlled trials: Comparisons 3–8.

| Outcome and subgroup | Studies | Participants | Method ($I^2$) | RR (95% CI) |
|----------------------|---------|--------------|----------------|-------------|
| **Comparison 3: IM versus IV maintenance dose of magnesium sulphate (pre-eclampsia eclampsia)** |         |              |                |             |
| 3.1 Perinatal death  |         |              |                |             |
| 3.1.1 Pritchard’s versus Zuspan’s regimen | 2       | 353          | F (0%)         | 0.94 (0.66, 1.32) |
| 3.1.2 Pritchard’s versus Sibai’s regimen  | 1       | 115          | F (NA)         | 0.90 (0.53, 1.53) |
| 3.1.3 Pritchard’s versus Bhattacharjee’s regimen  | 1       | 107          | F (NA)         | 1.28 (0.61, 2.65) |
| 3.1.4 Dhaka versus Zuspan’s regimen  | 1       | 41           | F (NA)         | 0.57 (0.16, 2.08) |
| 3.2 Stillbirth       |         |              |                |             |
| 3.2.1 Pritchard’s versus Zuspan’s regimen | 1       | 114          | F (NA)         | 0.79 (0.44, 1.40) |
| 3.2.2 Pritchard’s versus Sibai’s regimen  | 2       | 133          | F (0%)         | 0.80 (0.46, 1.41) |
| 3.2.3 Pritchard’s versus Bhattacharjee’s regimen  | 1       | 107          | F (NA)         | 1.18 (0.38, 3.63) |
| 3.2.4 Dhaka versus Zuspan’s regimen  | 1       | 41           | F (NA)         | 0.24 (0.03, 1.95) |
| 3.3 Neonatal death   |         |              |                |             |
| 3.3.1 Pritchard’s versus Zuspan’s regimen | 1       | 114          | F (NA)         | 2.52 (0.27, 23.47) |
| 3.3.2 Pritchard’s versus Sibai’s regimen  | 1       | 115          | F (NA)         | 2.56 (0.27, 23.93) |
| 3.3.3 Pritchard’s versus Bhattacharjee’s regimen  | 1       | 107          | F (NA)         | 1.37 (0.47, 4.06) |
| 3.3.4 Dhaka versus Zuspan’s regimen  | 1       | 41           | F (NA)         | 1.90 (0.19, 19.40) |
| 3.4 Apgar score < 7 at 1 minute |         |              |                |             |
| 3.4.1 Dhaka versus Zuspan’s regimen | 1       | 41           | F (NA)         | 0.32 (0.10, 1.01) |
| 3.5 Apgar score < 7 at 5 minutes |         |              |                |             |
| 3.5.1 Dhaka versus Zuspan’s regimen | 1       | 41           | F (NA)         | 0.38 (0.08, 1.74) |
| 3.6 Respiratory distress syndrome |         |              |                |             |
| 3.6.1 Dhaka versus Zuspan’s regimen | 1       | 41           | F (NA)         | 0.76 (0.24, 2.44) |
| 3.7 Jaundice          |         |              |                |             |
| 3.7.1 Dhaka versus Zuspan’s regimen | 1       | 41           | F (NA)         | 0.76 (0.24, 2.44) |
| 3.8 Hypotonia         |         |              |                |             |
| 3.8.1 Dhaka versus Zuspan’s regimen | 1       | 41           | F (NA)         | 0.48 (0.10, 2.32) |
| 3.9 NICU admission    |         |              |                |             |
| 3.9.1 Pritchard’s versus Zuspan’s regimen | 1       | 114          | F (NA)         | 0.98 (0.35, 2.73) |
| 3.9.2 Pritchard’s versus Sibai’s regimen  | 1       | 115          | F (NA)         | 1.00 (0.36, 2.78) |
| 3.9.3 Dhaka versus Zuspan’s regimen  | 1       | 41           | F (NA)         | 0.76 (0.24, 2.44) |
| **Comparison 4: Loading dose versus loading and maintenance doses of magnesium sulphate (pre-eclampsia eclampsia)** |         |              |                |             |
| 4.1 Perinatal death   | 3       | 632          | R (63%)        | 0.94 (0.33, 2.72) |
| 4.2 Stillbirth        | 3       | 803          | F (26%)        | 1.10 (0.77, 1.58) |
| 4.3 Neonatal death    | 2       | 462          | F (0%)         | 0.78 (0.43, 1.41) |
| 4.4 Neonatal death < 7 days | 1       | 402          | F (NA)         | 0.73 (0.30, 1.77) |
| 4.5 Apgar score < 7 at 0 minutes | 1       | 52           | F (NA)         | 1.07 (0.32, 3.54) |
| 4.6 Apgar score < 7 at 1 minute | 1       | 52           | F (NA)         | 0.86 (0.06, 12.98) |
| 4.7 Apgar score < 7 at 5 minutes | 2       | 406          | F (NA)         | 1.61 (0.72, 3.62) |
| 4.8 NICU admission for respiratory distress | 2       | 397          | F (0%)         | 1.02 (0.63, 1.65) |
| 4.9 NICU admission for early onset sepsis | 1       | 80           | F (NA)         | 1.00 (0.06, 15.44) |
| 4.10 NICU admission for late onset sepsis | 1       | 80           | F (NA)         | 3.00 (0.13, 71.51) |
| 4.11 NICU admission for meconium aspiration syndrome | 1       | 80           | F (NA)         | 1.00 (0.06, 15.44) |
| 4.12 NICU admission for birth asphyxia | 1       | 80           | F (NA)         | 0.33 (0.01, 7.95) |
| 4.13 NICU admission | 3       | 435          | F (0%)         | 0.94 (0.77, 1.15) |
| **Comparison 5: Serial intravenous boluses versus continuous intravenous maintenance of magnesium sulphate (pre-eclampsia)** |         |              |                |             |
| 5.1 Perinatal death   | 1       | 197          | F (NA)         | 0.44 (0.08, 2.34) |
| 5.2 Stillbirth        | 1       | 197          | F (NA)         | 0.29 (0.01, 7.09) |

(Continued)
Short versus standard maintenance course

This comparison included 1 trial, assessing magnesium sulphate for the treatment of eclampsia. Both groups received a 4-gram IV and 10-gram IM loading dose, followed by either a short maintenance course (2 doses of 5 grams IM 4 hours apart after birth or last seizure) or a standard maintenance course (5 grams IM every 4 hours for 24 hours after birth or last seizure) [29].

No clear difference between the short and standard maintenance course regimens was seen for stillbirth. No clear difference between the short and standard maintenance course regimens was seen for the only other secondary outcome reported, birth asphyxia (see Table 6 and S1 Appendix for effect estimates and forest plots).

Slower versus standard rate of loading dose

This comparison included 1 trial, assessing magnesium sulphate for fetal neuroprotection, and compared a slower (over 60 minutes) versus standard (over 20 minutes) rate of administering a 4-gram IV loading dose of magnesium sulphate (all women received a 1-gram-per-hour maintenance dose for 24 hours after birth/last seizure) [24].

No clear difference between a slower and standard rate of loading dose administration was seen for stillbirth (see Table 6 and S1 Appendix for effect estimate and forest plot).

Weaning versus no weaning

This comparison included 1 trial, assessing magnesium sulphate for the prevention of preterm birth (tocolysis), and compared weaning (by 1 gram IV per 4 hours) versus not weaning magnesium sulphate (all women received a 6-gram IV loading dose, and 2- to 3.5-gram IV maintenance dose per hour until tocolysis was achieved) [42].

No clear difference between weaning and no weaning was seen for Apgar score less than 7 at 5 minutes (see Table 6 and S1 Appendix for effect estimate and forest plot).
Evidence from non-randomised comparative studies

One hundred thirty-eight non-randomised studies were included: 5 non-randomised trials, 35 prospective cohort studies (7 with nested case–control analyses), 82 retrospective cohort studies (16 with nested case–control analyses), 8 non-concurrent cohort studies, and 8 case–control studies [62–199]. The characteristics of the studies and risk of bias assessments are detailed in S1 and S2 Tables.

There was substantial variation in the characteristics of these studies regarding participants, indications for use of magnesium sulphate (prevention or treatment of eclampsia: 30 studies; prevention of preterm birth (tocolysis): 28 studies; fetal neuroprotection: 25 studies; combination of aforementioned indications: 38 studies; unclear: 17 studies), comparison groups, outcomes assessed (and their definitions), and analysis methods employed. Methodological quality (specifically in relation to the risk of bias for reported review outcomes of interest) also differed across the studies, with overall judgements of unclear (specifically when only abstracts were available), high, moderate to high, and moderate risk of bias assigned to 43 studies, 49 studies, 35 studies, and 11 studies, respectively. The most common concerns across studies related to the potential for confounding (with no attempt to balance allocation between groups or match groups, and/or important confounding variables not taken into account in relevant outcome analyses), detection bias (with the consistent implementation of valid and reliable measures being unclear, and/or the absence of blinding of exposure or outcome assessors), and performance bias (with protocols not available to assess important variations).

The primary review outcome, perinatal death, was reported by 11 of the 138 non-randomised studies, 10 of which showed either a possible reduction (or lower rate) or no clear difference (or similar rate) in perinatal death among babies exposed to magnesium sulphate compared with no magnesium sulphate or a different magnesium sulphate regimen. A possible increase in perinatal death, specifically among babies exposed to >48 versus ≤48 grams of magnesium sulphate for tocolysis was shown in the 11th study (retrospective cohort of 127 babies, moderate to high risk of bias) [183]. See Table 7 and S3 Table for summaries of individual study results.

For the majority of secondary pre-specified and non-pre-specified adverse neonatal outcomes reported, the results from non-randomised studies were consistent with those observed in randomised controlled trials, with no clear differences (and in some cases, possible benefits of magnesium sulphate) observed. The direction of the findings (no clear difference, possible benefit, possible harm, or mixed) from the non-randomised studies are summarised in Table 8, with the detailed individual study results provided in S3 Table.

Seventeen of the 138 non-randomised studies (14 at moderate or moderate to high risk of bias, and 3 at unclear risk of bias [abstracts only]) observed a possible increase in the risk of adverse neonatal outcomes with antenatal magnesium sulphate, with some consideration of important confounding variables in relevant outcome analyses [68,73,84,90,106,109,129,132,134,140,152,153,173,180,184,191]. Potential increased risks with antenatal magnesium sulphate of 4 outcomes (discussed below) were observed by more than 1 study. For the remaining outcomes (nosocomial infection [184], enteral feeding intolerance [68], respiratory disease composite [153], pulmonary interstitial emphysema [191], early germinal matrix/intraventricular haemorrhage [180], thalamostrate or mineralising vasculopathy [152], and a composite neonatal adverse outcome [73]), single studies reported possible harms.

Potential increased risk of neonatal death before intensive care unit discharge, and of a composite outcome of neonatal death before intensive care unit discharge and/or necrotising enterocolitis, was shown among a subgroup of babies born less than 26 weeks gestation with...
| Study; design | Participants | Comparisons | Results summary |
|--------------|--------------|-------------|----------------|
| Adama-Hondegla 2013; RCS with CCS (N) | 178 babies born to women with eclampsia | (1) Babies living at seventh day of life, N = 147 babies, versus (2) stillbirths and neonatal deaths in first 7 days, N = 31 babies | MgSO₄ exposure: aOR 1.04, P > 0.05 |
| Alexander 2006; PCS | 87 babies born to women with eclampsia | (1) No gestational hypertension, no MgSO₄, N = 49 babies, versus (2) gestational hypertension, MgSO₄, N = 11 babies, versus (3) gestational hypertension, no MgSO₄, N = 27 babies | Perinatal death: 6.1% (3/49) versus 0% (0/11) versus 11.1% (3/27) |
| Cawyer 2019; RCS | 2,468 babies born to women with pre-eclampsia >32 weeks GA | (1) MgSO₄, N = 1,353 babies, versus (2) no MgSO₄, N = 1,115 babies | Perinatal or neonatal death: 0.1% (2/1,353) versus 0.2% (2/1,115), P = 1.00 |
| Chowdhury 2009; PCS | 529 babies born to women with eclampsia | (1) MgSO₄, Pritchard’s regimen, N = 406 babies, versus (2) MgSO₄, low dose IV regimen, N = 123 babies | Perinatal death: OR 1.58, 95% CI 0.93–2.61, P = 0.075 |
| Jung 2018; RCS | 184 babies born to women with ROM <32 weeks GA | (1) MgSO₄ for tocolysis, N = 143 babies, versus (2) no MgSO₄, N = 41 babies | Perinatal death: Overall: 7.0% (10/143) versus 19.5% (8/41), P = 0.0375; ROM at 23 to 27+6 weeks GA: 14.3% (9/63) versus 36.8% (7/19), P = 0.0651; ROM at 28 to 31+6 weeks GA: 1.25% (1/80) versus 4.5% (1/22), P = 0.0951 |
| Kamilya 2005; CCS (N) | 1,205 babies born to women with eclampsia | (1) Birth year 2002–2004 (almost universal MgSO₄), N = 481 babies, versus (2) birth year 1995–1997 (no MgSO₄), N = 724 babies | Perinatal death: 24.3% (117/481) versus 54.8% (397/724) |
| Kamyar 2016a; RCS (secondary analysis RCT) | 396 babies born to women with intrapartum clinical chorioamnionitis | (1) MgSO₄ for fetal neuroprotection, N = 192 babies, versus (2) placebo, N = 204 babies | Stillbirth or death by 1 year: Overall: aRR 1.68, 95% CI 0.85–3.32; ≤28 weeks GA: aRR 1.34, 95% CI 0.47–2.73 |
| Mitani 2011; RCS | 425 babies born between 22 and 31 weeks GA | (1) MgSO₄ for tocolysis, N = 236 babies, versus (2) no MgSO₄, N = 189 babies | Perinatal death: 5.5% (13/236) versus 9.0% (17/189), P = 0.185 |
| Okusanya 2012; NRT | 103 babies born to women with severe pre-eclampsia or eclampsia | Severe pre-eclampsia: (1) 10-g MgSO₄ LD, N = 25 babies, versus (2) 14-g MgSO₄ LD, N = 30 babies | Perinatal death, unclear reporting: Severe pre-eclampsia: (1) PMR 240 per 1,000 (6 deaths) versus (2) PMR 35 per 1,000 (1 death) |
| | | Eclampsia: (1) 10-g MgSO₄ LD, N = 29 babies, versus (2) 14-g MgSO₄ LD, N = 19 babies | Perinatal death, unclear reporting: Eclampsia: (1) PMR 241 per 1,000 (6 deaths, all IUFD) versus (2) 0 deaths |
| Scudiero 2000; RCS with CCS(N) | 127 babies born between 700 and 1,249 g, to women who received MgSO₄ for tocolysis | (1) Perinatal deaths, N = 18 babies, versus (2) survivors, N = 109 babies | MgSO₄ > 48 g: 72.2% (13/18) versus 45.0% (49/109), P = 0.03; MgSO₄ ≤ 48 g versus >48 g (multivariable model): OR 4.72, 95% CI 1.12 to 19.97, P = 0.035 |
| | | (1) MgSO₄ ≤ 24 g, N = 43 babies, versus (2) MgSO₄ > 24 to ≤ 48 g, N = 25 babies, versus (3) MgSO₄ > 48 g, N = 59 babies | Perinatal death (Cochrane–Armitage trend test, 1 versus 2 versus 3): 7.0% (5/3) versus 8.0% (2/25) versus 22.0% (13/59), P = 0.03; perinatal death (1 versus 2): 7.0% (3/43) versus 8.0% (2/25), P = 1.0 |
| Young 1977; NRT | 144 babies born to women with pre-eclampsia or eclampsia | (1) MgSO₄ IV bolus MD (2 g over 10 minutes every 1–2 hours), N = 97 babies, versus (2) MgSO₄ IV continuous MD (1 g per hour), N = 47 babies | Perinatal death: 2.1% (2/97) versus 2.1% (1/47) |

The bold studies were judged to be of higher quality (moderate to high risk of bias) and presented results adjusted for confounders for the relevant outcome; other studies were judged to be at high or unclear risk of bias and/or did not present adjusted results for the relevant outcome.

aOR, adjusted odds ratio; aRR, adjusted risk ratio; CCS(N), nested case–control study; CI, confidence interval; g, gram; GA, gestational age; IUFD, intrauterine fetal demise; IV, intravenous; LD, loading dose; MD, maintenance dose; MgSO₄, magnesium sulphate; NRT, non-randomised trial; OR, odds ratio; PCS, prospective cohort study; PMR, perinatal mortality ratio; RCS, retrospective cohort study; RCT, randomised controlled trial; ROM, rupture of the membranes.

https://doi.org/10.1371/journal.pmed.1002988.t007

... the use of antenatal magnesium sulphate for fetal neuroprotection (293 babies, in a retrospective cohort of 697 babies born less than 28 weeks gestation) [129]. A possible increased risk of the composite outcome spontaneous intestinal perforation or neonatal death was also shown among a subgroup of babies born less than 25 weeks gestation with higher cumulative
| Outcome | Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen |
|---------|------------------------------------------------------------------------------------------|
|         | Studies showing no clear difference | Studies showing possible benefit | Studies showing possible harm |
| Stillbirth | Brazy 1982; Chowdhury 2009; Jung 2018<sup>▲</sup> | Jung 2018<sup>▲</sup>; Shamsuddin 2005<sup>▲</sup> | Das 2015<sup>▲</sup> |
| Neonatal death or death before discharge | Alston 2016; Ambadkar 2019; Basu 2012; Bertello Gracco 2019<sup>▲</sup>; Brazy 1982; Canterino 1999; Chowdhury 2009<sup>▲</sup>; De Jesus 2015<sup>▲</sup>; del Moral 2007; de Veciana 1995<sup>▲</sup>; Drassinower 2015<sup>▲</sup>; Elimian 2002<sup>▲</sup>; Elliott 2003; Parkhoun 2001; Gibbins 2013; Girsen 2015; Gonzalez-Quintero 2001; Hechtman 2002<sup>▲</sup>; Hong 2019; James 2015; Jazayeri 2003; Jung 2018<sup>▲</sup>; Kamyar 2015a; Kamyar 2015b; Kamyar 2016a; Kamyar 2016b<sup>▲</sup>; Lam 2015; Lee 2013; Lloreda-Garcia 2016; Mitani 2011; Morag 2016; Narasimhulu 2017; Nassar 2006<sup>▲</sup>; Özlü 2019; Paneth 1997; Rantonen 2001; Shalabi 2017<sup>▲</sup>; Shokry 2010; Suh 2015; Weisz 2015<sup>▲</sup>; Whitsel 2004; Yokoyama 2010 | Downey 2017; Garcia Alonso 2018; Grether 1998; Shalabi 2017<sup>▲</sup>; Stockley 2018; Weisz 2015<sup>▲</sup> | Das 2015<sup>▲</sup>; Kamyar 2016b<sup>▲</sup>; Lipsitz 1971<sup>▲</sup>; Rattray 2014; Rauf 2017 |
| Apgar score < 7 at 1 minute (or ≤ 5) | Chung 2014<sup>▲</sup>; Gibbins 2013; Lloreda-Garcia 2016; Mitani 2011; Morag 2016; Narasimhulu 2017 | Chun 2014<sup>▲</sup>; Das 2015<sup>▲</sup>; Girsen 2015; Lipsitz 1971<sup>▲</sup> | |
| Apgar score < 7 at 5 minutes (or ≤ 5 or < 6) | Canterino 1999; Chung 2014<sup>▲</sup>; Cuff 2018<sup>▲</sup>; de Veciana 1995<sup>▲</sup>; Drassinower 2015<sup>▲</sup>; Elimian 2002<sup>▲</sup>; Gibbins 2013; Jung 2018; Lloreda-Garcia 2016; McPherson 2014<sup>▲</sup>; Mitani 2011; Narasimhulu 2017; Nassar 2006<sup>▲</sup>; Nelson 1995; Okusanya 2012<sup>▲</sup>; Rhee 2012; Schanler 1997; Stockley 2018; Weisz 2015<sup>▲</sup> | Jeanneteau 2014; Shalabi 2017 | Chunc 2014<sup>▲</sup>; Das 2015<sup>▲</sup>; Girsen 2015; Lipsitz 1971<sup>▲</sup>; Morag 2016 |
| Birth asphyxia | McGuiness 1980 | Shamsuddin 2005<sup>▲</sup> | |
| Meconium at birth | Greenberg 2013; Jazayeri 2003 | | |
| Intubation | Basu 2012; De Jesus 2015<sup>▲</sup>; Derks 2016; Morag 2016; Narasimhulu 2017; Weisz 2015<sup>▲</sup> | Bajaj 2018; Drassinower 2015; Weisz 2015<sup>▲</sup> | Das 2015<sup>▲</sup>; Rauf 2017; Weisz 2015<sup>▲</sup> |
| Intubation (duration) | de Veciana 1995 | O Reilly 2016<sup>▲</sup> | O Reilly 2016<sup>▲</sup> |
| Resuscitation | Basu 2012; Brookfield 2015<sup>▲</sup>; De Jesus 2015<sup>▲</sup>; García Alonso 2018<sup>▲</sup>; Gibbins 2013; Lloreda-Garcia 2016; McPherson 2014<sup>▲</sup>; Narasimhulu 2017; Özlü 2019; Weisz 2015<sup>▲</sup> | Bajaj 2018; De Silva 2018 | Lipszt 1971<sup>▲</sup>; Weisz 2015<sup>▲</sup> |
| Oxygen bag, mask, or both (resuscitation) | Bajaj 2018; Drassinower 2015; Riaz 1998; Weisz 2015<sup>▲</sup> | Weisz 2015<sup>▲</sup> | |
| Chest compressions (resuscitation) | Drassinower 2015; Stockley 2018; Weisz 2015<sup>▲</sup> | Bajaj 2018; Weisz 2015<sup>▲</sup> | |
| Adrenaline (resuscitation) | Stockley 2018; Weisz 2015<sup>▲</sup>^ | Jeanneteau 2014; Weisz 2015<sup>▲</sup> | |
| Score for Neonatal Acute Physiology > 10 or 20 in first 24 hours | Stockley 2018; Weisz 2015<sup>▲</sup> | Deering 2005; Shalabi 2017; Weisz 2015<sup>▲</sup> | |
| Delayed adaptation | Lai 2017; Riaz 1998 | | Brazy 1982 |
| Respiratory distress syndrome | Alston 2016; Ambadkar 2019; Bozkurt 2016; Brookfield 2016; Canterino 1999; De Jesus 2015<sup>▲</sup>; de Veciana 1995<sup>▲</sup>; Drassinower 2015<sup>▲</sup>; Elimian 2002<sup>▲</sup>; Girsen 2015; Gonzalez-Quintero 2001; Gunsey 2015; Imamoglu 2014; Jazayeri 2003; Jung 2018; Kamyar 2015a; Lee 2013; McPherson 2014<sup>▲</sup>; Mitani 2011; Rantonen 2001; Schanler 1997; Shokry 2010; Suh 2015; Yokoyama 2010 | de Veciana 1995<sup>▲</sup>; Özlü 2019 | |

(Continued)
Table 8. (Continued)

| Outcome                                          | Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen |
|--------------------------------------------------|---------------------------------------------------------------------------------------------|
|                                                  | Studies showing no clear difference | Studies showing possible benefit | Studies showing possible harm |
| Respiratory depression                           | Bertello Grecco 2019*                  | Das 2015*                        |
| Surfactant use                                   | delValle 1998; Elimian 2002*; Garcia Alonso 2018; Lloreda-Garcia 2016; Rantonen 2001; Shokry 1997; Weisz 2015* |                                |
| Ventilation                                      | Brookfield 2016; De Jesus 2015*; Drassnower 2015; Garcia Alonso 2018; Girsen 2015; Havranek 2011; James 2015; Lee 2013; Lloreda-Garcia 2016*; McPherson 2014*; Nunes 2018; Olzü 2019; Rantonen 2001; Schanler 1997; Shokry 2010 | De Jesus 2015*; Lloreda-Garcia 2016*; Rauf 2017*; Shalabi 2017 |
|                                                  |                                             | Lipsitz 1971*; Lloreda-Garcia 2016*; Rauf 2017* |
| Ventilation (duration)                          | Black 2006; De Jesus 2015; Kimberlin 1998; Olzü 2019; Suh 2015 |                                |
| Methylxanthine use or duration                   | Black 2006; Havranek 2011; Imamoglu 2014; Schanler 1997 |                                |
| Chronic lung disease or bronchopulmonary dysplasia | Alston 2016; Basu 2012; Bozkurt 2016; De Jesus 2015; Edwards 2018; Garcia Alonso 2018; James 2015; Jung 2018; Kamyar 2015a; Kamyar 2016a; McPherson 2014*; Olzü 2019; Shalabi 2017; Stockley 2018; Suh 2015; Weisz 2015 | Narasimhulu 2017; Stetson 2019 |
| Oxygen use (at 28 days, 36 weeks, or discharge)  | Kimberlin 1998; Morag 2016; Schanler 1997 |                                |
| Oxygen use (duration)                            | De Jesus 2015; Olzü 2019; Suh 2015 |                                |
| Steroid use (dexamethasone or hydrocortisone)    | Mikhael 2019a; Rantonen 2001; Rattray 2014; Shalabi 2017 |                                |
| Apnoea                                           | Bozkurt 2016; Riaz 1998; Wutthigate 2017* |                                |
| Pulmonary haemorrhage                            | De Jesus 2015; James 2015 |                                |
| Necrotising enterocolitis                        | Alston 2016; Bozkurt 2016; Brazy 1982; De Jesus 1957; delValle 1998; de Veciana 1995; Downey 2017; Edwards 2018; Elimian 2002*; Elliott 2003; Garcia Alonso 2018; Ghidini 2001; Gursoy 2015; Hong 2019; James 2015; Jazayeri 2003; Jung 2018; Kamyar 2015a; Kamyar 2016a; Kamyar 2016b; Kimberlin 1998; Lee 2013; Lloreda-Garcia 2016; McPherson 2014*; Mikhael 2019*; Morag 2016; Narasimhulu 2017; Olzü 2019; Schanler 1997; Shalabi 2017; Stockley 2018; Suh 2015; Weisz 2015; Yokoyama 2010 | Moschos 2001; Wiswell 1996 |
| Spontaneous intestinal perforation               | Downey 2017; Mikhael 2019a; Shalabi 2017 | Rattray 2014 |
| Composite of necrotising enterocolitis/spontaneous intestinal perforation or death | Kamyar 2016b*; Mikhael 2019a* | Downey 2017; Mikhael 2019a* | Kamyar 2016b*; Rattray 2014* |
| Necrotising enterocolitis/spontaneous intestinal perforation–associated death | Hong 2019; Shalabi 2017 |                                |
| Sepsis                                           | Alston 2016; Bozkurt 2016; De Jesus 2015; Elimian 2002*; Girsen 2015; James 2015; Jazayeri 2003; Jung 2018; Kamyar 2016a; Lloreda-Garcia 2016; Mikhael 2019*; Morag 2016; Olzü 2019; Rantonen 2001; Riaz 1998; Stockley 2018; Teng 2006; Weisz 2015 | Whitsel 2004 |

(Continued)
Table 8. (Continued)

| Outcome                        | Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen | Studies showing no clear difference | Studies showing possible benefit | Studies showing possible harm |
|--------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------|------------------------------|
| Antibiotic use                | Elimian 2002^; Greenberg 2013                                                               |                                    |                                 |                              |
| Hypoglycaemia                 | Bozkurt 2016; Grimbley 2015                                                               |                                    |                                 |                              |
| Feeding intolerance           | Gursoy 2015; Ozłü 2019; Riaz 1998                                                             | Belden 2017^                        |                                 |                              |
| Delayed stoolsing             | Lloreda-Garcia 2016^; Lloreda-Garcia 2016^                                                  |                                    |                                 |                              |
| Meconium passage delay        | Ambadkar 2019; Lloreda-Garcia 2016                                                          |                                    |                                 |                              |
| Ileus                          | Sahin 2001                                                                                   |                                    |                                 |                              |
| Patent ductus arteriosus      | Basu 2012; Bozkurt 2016; delValle 1998; Elimian 2002^; García Alonso 2018; Gursoy 2015; Imamoglu 2014; James 2015; Katayama 2011^; Lee 2013^; Ozłü 2019; Schanler 1997; Yokoyama 2010 | Qasim 2017                          | Bazy 1982; del Moral 2007; Gonzalez-Quintero 2001; Katayama 2011^; Lee 2013; Narasimhulu 2017; Shokry 2010 |                              |
| Patent ductus arteriosus (treated) | De Jesus 2015; del Moral 2007; delValle 1998; Katayama 2011^; Lee 2013; Lloreda-Garcia 2016; Mikhael 2019^; Shalabi 2017; Suh 2015 |                                    | Bonta 2000^                     |                              |
| Hypotension                   | Bazy 1982; Derks 2016; Drassinower 2015; Gursoy 2015; Morag 2016; Teng 2006                 | De Jesus 2015                       | Narasimhulu 2017                |                              |
| Hypertension                  | Gursoy 2015                                                                                   | Gursen 2015                         | Brown 2019                      |                              |
| Inotrope use                  | Imamoglu 2014; James 2015; Shokry 2010                                                      |                                    | Greenberg 2013; Rasch 1982      |                              |
| Intravenous fluids and/or nutritional support needed | Greenberg 2013; Havranek 2011; Imamoglu 2014 |                                    |                                  |                              |
| Phototherapy                  | Greenberg 2013; Havranek 2011; Imamoglu 2014                                                  |                                    | Greenberg 2013; Rasch 1982      |                              |
| Retinopathy of prematurity    | Basu 2012; Bozkurt 2016; Cuff 2018^; De Jesus 2015; Elliott 2003; Garcia Alonso 2018; Jung 2018; Kamyar 2015^; Kimberlin 1998; Lee 2013; McPherson 2014^; Narasimhulu 2017; Ozbek 2019; Shalabi 2017^; Stockley 2018; Suh 2015; Weisz 2015; Yokoyama 2010 | Shalabi 2017^                       | Rauf 2017                       |                              |
| Hypotonia                     | Bertello Grecco 2019^; Drassinower 2015; Gursen 2015; Ginsen 2015; Nassar 2006^             |                                    | Ambadkar 2019; Bazy 1982; Del Moral 2007; Rauf 2017; Riaz 1998 |                              |
| Seizure                       | Drassinower 2015; Ginsen 2015; Kimberlin 1998; McPherson 2014^; Rauf 2017                  |                                    | Shokry 2010                     |                              |
| Encephalopathy                | Gursen 2015; Rantanen 2001; Rauf 2017                                                       |                                    |                                 |                              |
| Intraventricular haemorrhage  | Alston 2016; Black 2006; De Jesus 2015; delValle 1998; de Veciana 1995; Drassinower 2015; Edwards 2018; Elliott 2003; Gano 2016; Garcia Alonso 2018; Gaspar 2017; Gonzalez-Quintero 2001; Gursoy 2015; Hom 2018; Imamoglu 2014; Jazayeri 2003; Jung 2018^; Kamyar 2015^; Lee 2013; Leviton 1997; Martin 1998; McPherson 2014^; Mitani 2011^; Nassar 2006^; Nelson 1995; Ozbek 2019; Paneth 1997; Schanler 1997; Stetson 2019; Stockley 2018; Suh 2015; Yokoyama 2010 | Jung 2018^; Kuban 1992; Perlman 1995; Petrova 2012; Rantanen 2001; Rauf 2017; Shokry 2010 | Salafia 1995 |                              |
| Intraventricular haemorrhage grade 3 or 4 | del Moral 2007; Downey 2017; Gano 2016; James 2015; Jung 2018; Kamyar 2016a; Kimberlin 1998; McPherson 2014^; Mikhail 2019^; Narasimhulu 2017; Ozbek 2019; Rantanen 2001; Stockley 2018; Weintraub 2001 | Gasparyan 2017; Perlman 1995; Sarkar 2009; Wiswell 1996 | Cuff 2018^; Khodapanahandeh 2008 |                              |

(Continued)
Table 8. (Continued)

| Outcome                              | Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen |
|--------------------------------------|-----------------------------------------------------------------------------------------------|
|                                      | Studies showing no clear difference | Studies showing possible benefit | Studies showing possible harm |
| Periventricular leucomalacia         | Bozkurt 2016; De Jesus 2015; del Moral 2007; delValle 1998; Garcia Alonso 2018; Jung 2018; Kamyar 2015a; Kamyar 2016a; Lee 2013; Mitani 2011^; Narasimhulu 2017; Rauf 2017; Suh 2015; Wiswell 1996 | FinSmith 1997; Jung 2018^; Murata 2005 |
| Intraventricular haemorrhage or      | Basu 2012; Canterino 1999^; Elimiin 2002^                                                     |
| periventricular leucomalacia         | Bozkurt 2016; Canterino 1999^; Morag 2016; Shalabi 2017^; Weizs 2015                          |
| Intraventricular haemorrhage grade 3 | Koksal 2002; Shalabi 2017^; Wiswell 1996                                                     |
| and/or periventricular leucomalacia  |                                                                                             |
| Hypocalcaemia                         | Cho 2014; Lee 2015; McGuinness 1980                                                          |
| Bone abnormalities                    | Yokoyama 2010                                                                                |
| Hearing impairment or hearing test   | Jung 2018                                                                                    |
| failure                              | Leung 2016                                                                                   |
| Composite adverse outcomes           | Drassinower 2015; Duffy 2012; Kamyar 2015a; Kamyar 2015b; Kamyar 2015c; Kamyar 2016a; Mitani |
| NICU admission                        | 2011^; Narasimhulu 2017; Palatnik 2019; Rizzolo 2019; Sakae 2017^; Weizs 2015                |
| NICU duration                         | Ambadkar 2019^; Bertello Grecco 2019^; Caywer 2019; Chun 2014^; Gibbins 2013; Lai 2017; |
| Hospital stay duration                | McPherson 2014; Rantone 2001; Riaz 1998; Schanler 1997; Suh 2015                            |
| Other (outcomes reported by single   | Ambadkar 2019^; Chun 2014^; Das 2015^; Girsen 2015; Greenberg 2011^; Greenberg 2013^; Rhee |
| studies)                              |                                               |
|                                       | Boyle 2018; Sakae 2017^                                                                      |
| Hospital stay duration                | Narasimhulu 2017                                                                            |
| Other (outcomes reported by single    | Brazy 1982; Girsen 2015                                                                      |
| studies)                              |                                               |

The bold studies were judged to be of higher quality (moderate or moderate to high risk of bias) and presented results adjusted for confounders for the relevant outcomes; other studies were judged to be at high or unclear risk of bias and/or did not present adjusted results for the relevant outcomes.

^Indicates where studies assessed different magnesium sulphate regimens or 1 or more characteristics of the regimen (such as dose, duration, timing, or indication for use).

^Indicates where studies demonstrated mixed findings (such as in different subgroups of the population).

NICU, neonatal intensive care unit.

https://doi.org/10.1371/journal.pmed.1002988.1008

Antenatal magnesium sulphate doses for fetal neuroprotection (non-concurrent cohort of 155 babies born less than 1,000 grams) [173].

A possible increased risk of patent ductus arteriosus was observed with magnesium sulphate given for pre-eclampsia (retrospective cohort of 81 ‘very low birthweight’ babies; abstract
only) [140] or for pre-eclampsia or tocolysis (retrospective cohort of 941 babies born 500 to 1,000 grams) [90]. Further, a possible increased risk of patent ductus arteriosus in babies born 26 weeks gestation or later was shown with cumulative antenatal magnesium sulphate doses for pre-eclampsia or tocolysis of at least 50 grams (retrospective cohort of 941 babies born 500 to 1,000 grams) [90]. Potential increased risk of symptomatic patent ductus arteriosus, and of failure of early closure of the ductus arteriosus, was also observed with the use of antenatal magnesium sulphate for tocolysis (retrospective cohort of 160 babies born less than 28 weeks gestation, who all received indomethacin prophylaxis) [132].

A potential increased risk of intraventricular haemorrhage grade 3 or 4 was observed with antenatal magnesium sulphate for tocolysis (case–control study of 121 babies born less than 1,500 grams) [134], and with a higher dose regimen of antenatal magnesium sulphate for fetal neuroprotection (6-gram IV loading dose and 2-gram-per-hour IV maintenance dose for 12 hours versus 4-gram IV loading dose only) (retrospective cohort, including 54 babies exposed to magnesium sulphate within 12 hours of birth) [84].

A possible increased risk of neonatal intensive care unit admission with the use of antenatal magnesium sulphate for pre-eclampsia was observed (retrospective cohorts of 264 babies and 2,166 babies born at 37 weeks gestation or later) [106,109]. Further increased risks of neonatal intensive care unit and special care unit admission were observed with higher total hours, higher total doses, more than 12 hours, and more than 30 grams of antenatal magnesium sulphate for pre-eclampsia (retrospective cohort of 242 babies born at 35 weeks gestation or later) [108].

Evidence from case reports

Nineteen reports describing a total of 134 babies exposed to antenatal magnesium sulphate with adverse outcomes were included [200–218] (see Table 9; the detailed characteristics of cases are presented in S4 Table).

Clinical features of neonatal hypermagnesemia, magnesium ‘toxicity’, or magnesium ‘intoxication’ at birth were the focus of 5 reports (35 neonates), in which antenatal magnesium sulphate was given for pre-eclampsia/eclampsia (with exposure durations and doses ranging from 3.5 to 46 hours and 11 to 60.4 grams prior to birth, respectively) [202,205,206,213,218], and were variably described throughout the remaining reports. These included low Apgar scores, apnoea, cyanosis, hypotonia, and/or hyporeflexia, with or without the need for active resuscitation and calcium gluconate administration.

Table 9. Summary of main adverse outcomes from case reports.

| Outcome                                      | Indication for use: studies |
|----------------------------------------------|----------------------------|
| Neonatal death                               | Tocolysis: Herschel 2001    |
|                                              | Pre-eclampsia/eclampsia: Kurtoglu 2000 |
| Cardiopulmonary arrest after gentamicin exposure following hypermagnesemia at birth | Pre-eclampsia: L’Hommedieu 1983; Rasch 1981 |
| Clinical features of magnesium ‘toxicity’ or ‘intoxication’ at birth (such as apnoea, cyanosis, hypotonia, and/or hyporeflexia) | Pre-eclampsia/eclampsia: Brady 1967; Cruz 2009; Lipsitz 1967; Teng 1989 |
|                                              | Not clear: Jashi 2014       |
| Microcolon or ‘meconium-plug syndrome’       | Pre-eclampsia/eclampsia: Amodio 1986; Krasa 1996; Sokal 1972 |
| Nonoliguric hyperkalaemia                    | Pre-eclampsia: Tanaka 2018  |
| Bone abnormalities with prolonged magnesium sulphate for tocolysis | Tocolysis: Cumming 1989; Kaplan 2006; Kogan 2003; Lamm 1988; Malaeb 2004 |
|                                              | Not clear: Ahmad 2013       |

https://doi.org/10.1371/journal.pmed.1002988.t009
Two reports described neonatal death following antenatal magnesium sulphate exposure. In the first report, death was considered to be related to ‘the toxic effects of magnesium on the myocardium’ when given for tocolysis (4-gram IV loading dose followed by 2.5-gram-per-hour IV maintenance dose for approximately 1 day: 51.4 grams total) [204], and in the second, 1 death (of 7) was attributed to ‘overdose’ (unclear dose/regimen) of magnesium sulphate when given for pre-eclampsia/eclampsia [210].

In the context of hypermagnesemia at birth (following exposure to a total of 24 to 28 grams of magnesium sulphate for pre-eclampsia), neonatal gentamicin administration for suspected sepsis was associated with respiratory arrest and cardiac arrest in 2 reports [211,215]. Other specific adverse outcomes attributed to antenatal magnesium sulphate exposure included:

- Microcolon or meconium-plug syndrome (3 reports, 14 neonates, when given for pre-eclampsia/eclampsia: 25 to 41 grams in the day prior to birth in 1 report; regimen not described in 2 reports) [201,209,216];
- Nonoliguric hyperkalaemia (1 report, 1 neonate, when given for pre-eclampsia: 0.1 gram to 2 grams per hour IV for 12 days) [217];
- Bone abnormalities (commonly metaphyseal osteopenia, in some cases leading to fracture) (6 reports, 35 neonates, when given for tocolysis: ranging from 1 to 4 grams per hour for between 8 and 13 weeks) [200,203,207,208,212,214].

**Discussion**

Overall, no clear difference in our primary review outcome, perinatal death, was shown in the randomised trials comparing antenatal magnesium sulphate with placebo/no treatment, nor in regimen comparisons in randomised trials. While 11 of the 138 non-randomised studies reported on perinatal death, only 1 cohort study (at moderate to high risk of bias) observed a possible increased risk of perinatal death, with high-dose (more than 48 grams) antenatal magnesium sulphate exposure for tocolysis [183].

Results for secondary adverse neonatal outcomes were reassuring, with very few clear differences observed between antenatal magnesium sulphate and placebo/no treatment or between different magnesium sulphate regimens. Where possible harms of magnesium sulphate were seen, commonly no confounders were taken into account (and studies were judged to be at high risk of bias), study samples were small (less than 200 babies), and/or differences were observed in (non-formal) subgroup analyses only. Non-randomised studies identified a limited number of outcomes justifying further evaluation, such as from large, high-quality studies (prospective cohorts, individual participant data meta-analyses, or randomised trials of regimen comparisons). These included neonatal death and intestinal morbidity in very pre-term neonates with exposure for fetal neuroprotection, patent ductus arteriosus in very pre-term or very low birthweight neonates with exposure for pre-eclampsia or tocolysis, and intensive care unit admission in term neonates with exposure for pre-eclampsia. Case reports suggested an association between neonatal bone abnormalities and long-term, high-dose exposure to antenatal magnesium sulphate for tocolysis.

We are not aware of any other published systematic reviews with a focus on potential adverse outcomes for neonates following antenatal magnesium sulphate exposure, though we identified 3 review registrations focused specifically on magnesium sulphate for tocolysis and the outcomes neonatal respiratory depression (CRD42017058912), patent ductus arteriosus (CRD42017060049), and bone abnormalities (CRD42017062550) [18]. Three previous systematic reviews have assessed ‘adverse events’ [13], ‘side effects’ [219], and ‘safety’ [220] for
women, and a further systematic review has assessed the effects of antenatal magnesium sulphate specifically on fetal heart rate parameters, finding a small negative effect on rate, variability, and accelerative pattern, ‘not sufficient clinically to warrant medical intervention’ [14].

Our review findings are consistent with those from the relevant Cochrane reviews comparing antenatal magnesium sulphate with placebo/no treatment, or different magnesium sulphate regimens [1,2,4,9,221], though our review includes a wider range of outcomes. As was observed in our review’s tocolysis subgroup for perinatal death, the Cochrane review assessing magnesium sulphate for tocolysis demonstrated a borderline increased risk of fetal, neonatal, or infant death with antenatal magnesium sulphate [9].

A recent non-systematic narrative review evaluated ‘whether antenatal MgSO₄ is beneficial or harmful’ in extremely and very preterm neonates [222]. Relevant systematic reviews, meta-analyses, randomised controlled trials, and observational studies were retrieved, with a broad search strategy focused on neuroprotection and cerebral palsy, necrotising enterocolitis, and spontaneous intestinal perforation. The narrative review suggested that current evidence supports the neuroprotective role of antenatal magnesium sulphate for preterm neonates, and that, while the effects are ‘controversial’ and ‘not well established’, a ‘high index of suspicion of gastrointestinal complications in extremely preterms, particularly < 26 weeks of gestation’ is recommended [222]. While our review similarly identified a possibility of harm, the relevant studies were of questionable methodological quality, and our systematic review included additional reports (of higher quality, and involving much larger cohorts) that indicated no increased risk of intestinal morbidity.

The findings of this review are reassuring and can be considered in conjunction with those from relevant reviews demonstrating a clear benefit of antenatal magnesium sulphate [1,2,4], and current international clinical practice guideline recommendations [3,7]. Our review findings of possible adverse outcomes with long-term, high-dose use for tocolysis have implications for settings with continued use for this indication [8] in spite of the absence of benefit shown in systematic reviews and international guidance [7–9].

**Strengths and limitations**

The main limitations of our review relate to missing data for important outcomes across most studies, the inclusion of published data only, and the heterogeneity of included studies.

Of the 40 randomised trials included in this review, our primary outcome (perinatal death) was reported by 22 (55%); it was reported by only 11 (8%) of the 138 included non-randomised studies. Aside from related mortality outcomes (stillbirth and neonatal death), all other adverse outcomes were reported sparsely, by less than a third of trials, with many outcomes reported by single trials only. While a broader range of adverse neonatal outcomes were reported by the non-randomised studies, apart from neonatal death (50 studies), intraventricular haemorrhage (39 studies), and necrotising enterocolitis (36 studies), all other outcomes were reported by less than a fifth of studies, again, with many reported by single studies only.

In addition to missing data for important outcomes across most studies, a further limitation includes the number of studies with relatively small sample sizes comparing different antenatal magnesium sulphate regimens. Moreover, many studies assessing antenatal magnesium sulphate for relevant indications were not included due to lack of reporting of adverse neonatal outcomes.

We searched extensively across multiple databases and reviewed reference lists for additional reports; however, we did not seek unpublished data. Recent evidence has suggested that while much adverse event information remains unpublished, inclusion of such data generally does not change the direction or statistical significance of pooled risk estimates [223].
we were not able to fully evaluate non-English publications without available translations for inclusion, we have provided a list of these for readers to consider (S3 Text).

As the aim of the review was to provide a comprehensive, general view of potential unintended adverse outcomes, we designed this review with broad scope [15,16]. This presented challenges, including the number of diverse outcomes, inconsistent reporting, and the vast quantities of heterogeneous data. The study characteristics (including designs, settings, participating women and neonates, and antenatal magnesium sulphate regimens) varied greatly, and reporting was commonly incomplete. The ability to conduct subgroup analyses for the randomised trials was limited, and we did not inappropriately pool data from non-randomised studies. We conducted this review in accordance with recommendations for systematic reviews of adverse events [15–17], and of randomised and non-randomised studies more generally [224]. Our evaluation thus provides a firm basis for any further, narrowly focused studies of specific outcomes and characteristics.

Conclusions
In conclusion, our findings do not support any clear associations between perinatal death or other adverse neonatal outcomes and antenatal magnesium sulphate exposure when given for the beneficial indications of maternal neuroprotection in pre-eclampsia/eclampsia and fetal neuroprotection in cerebral palsy prevention. To further inform safety recommendations of this widely used treatment in pregnancy, future research should be directed towards identified research gaps surrounding specific adverse neonatal outcomes and the impact of particular regimen, pregnancy, and/or birth characteristics.

Supporting information
S1 Appendix. Forest plots and funnel plots for comparisons 1–8. 
(DOCX)

S1 Fig. Risk of bias for randomised controlled trials. Risk of bias summary showing judgements about each risk of bias item for the 40 included randomised trials. Green represents ‘low risk of bias’; yellow, ‘unclear risk of bias’; red, ‘high risk of bias’. 
(TIF)

S1 PRISMA Checklist. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. 
(DOCX)

S1 Table. Characteristics of included studies. 
(DOCX)

S2 Table. Risk of bias of included studies. 
(DOCX)

S3 Table. Adverse outcomes from non-randomised studies. 
(DOCX)

S4 Table. Adverse outcomes from case reports. 
(DOCX)

S1 Text. Protocol. 
(PDF)
S2 Text. Search strategies.

(DOCX)

S3 Text. Articles excluded at full-text screening due to absence of English translation.

(DOCX)

S4 Text. References for included studies.

(DOCX)

Author Contributions

**Conceptualization:** Emily Shepherd, Deepak Manhas, Anne Synnes, Philippa Middleton, Maria Makrides, Caroline A. Crowther.

**Data curation:** Emily Shepherd, Rehana A. Salam, Deepak Manhas, Anne Synnes.

**Formal analysis:** Emily Shepherd.

**Funding acquisition:** Emily Shepherd, Philippa Middleton, Maria Makrides, Caroline A. Crowther.

**Investigation:** Emily Shepherd, Rehana A. Salam, Deepak Manhas, Anne Synnes.

**Methodology:** Emily Shepherd, Deepak Manhas, Anne Synnes, Philippa Middleton, Maria Makrides, Caroline A. Crowther.

**Project administration:** Emily Shepherd.

**Resources:** Emily Shepherd.

**Software:** Emily Shepherd.

**Supervision:** Emily Shepherd.

**Writing – original draft:** Emily Shepherd.

**Writing – review & editing:** Emily Shepherd, Rehana A. Salam, Deepak Manhas, Anne Synnes, Philippa Middleton, Maria Makrides, Caroline A. Crowther.

References

1. Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;(11):CD000025. https://doi.org/10.1002/14651858.CD000025.pub2 PMID: 21069663

2. Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev. 2010;(8):CD007388. https://doi.org/10.1002/14651858.CD007388.pub2 PMID: 20687086

3. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organization; 2011.

4. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009;(1):CD004661. https://doi.org/10.1002/14651858.CD004661.pub3 PMID: 19160238

5. Jayaram PM, Mohan MK, Farid I, Lindow S. Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. J Perinat Med. 2018; 47(3):262–9. https://doi.org/10.1515/jpm-2018-0174 PMID: 30352042

6. Medley N, Poljak B, Mammarella S, Alfrevic Z. Clinical guidelines for prevention and management of preterm birth: a systematic review. Br J Obstet Gynaecol. 2018; 125(11):1361–9.

7. World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes. Geneva: World Health Organization; 2015.
8. Elliott JP, Morrison JC, Bofill JA. Risks and benefits of magnesium sulfate tocolysis in preterm labor (PTL). AIMS Public Health. 2016; 3(2):348–56. https://doi.org/10.3934/publichealth.2016.2.348 PMID: 29546168

9. Crowther CA, Brown J, McKinlay CJ, Middleton P. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev. 2014;(8):CD001060. https://doi.org/10.1002/14651858.CD001060.pub2 PMID: 25126773

10. Hutchinson HT, Nichols MM, Kuhn CR, Vasicka A. Effects of magnesium sulfate on uterine contractility, intrauterine fetus, and infant. Am J Obstet Gynecol. 1964; 88:747–58. https://doi.org/10.1016/0002-9378(64)90608-8 PMID: 14130338

11. Tsang RC. Neonatal magnesium disturbances. Am J Dis Child. 1972; 124(2):282–93. https://doi.org/10.1001/archpedi.1972.02110140132019 PMID: 4559534

12. Van Laecke S. Hypomagnesemia and hypermagnesemia. Acta Clin Belg. 2019; 74(1):41–7. https://doi.org/10.1080/17843286.2018.1516173 PMID: 30220246

13. Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy Childbirth. 2013; 13:195. https://doi.org/10.1186/1471-2393-13-195 PMID: 24139447

14. Nensi A, De Silva DA, von Dadelszen P, Sawchuck D, Synnes AR, Crane J, et al. Effect of magnesium sulphate on fetal heart rate parameters: a systematic review. J Obstet Gynaecol Can. 2014; 36(12):1055–64. https://doi.org/10.1016/S1701-2163(15)30382-0 PMID: 25668040

15. Loke YK, Golder SP, Vandenbroucke JP. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources. Ther Adv Drug Saf. 2011; 2(2):59–68. https://doi.org/10.1177/2042098611401129 PMID: 25083202

16. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol. 2007; 7:32. https://doi.org/10.1186/1471-2288-7-32 PMID: 17615054

17. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016; 352:i157. https://doi.org/10.1136/bmj.i157 PMID: 26830668

18. Centre for Reviews and Dissemination. PROSPERO: international prospective register of systematic reviews. York: Centre for Reviews and Dissemination; 2019 [cited 2019 May 3]. https://www.crd.york.ac.uk/prospero/

19. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). Cochrane Collaboration; 2011 [cited 2019 Nov 11]. https://handbook-5-1.cochrane.org/

20. Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions or exposures: further development of the RTI Item Bank. Rockville (MD): Agency for Healthcare Research and Quality; 2013 Aug.

21. Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre; 2014.

22. Abdul M, Nasir U, Khan N, Yusuf M. Low-dose magnesium sulphate in the control of eclamptic fits: a randomized controlled trial. Arch Gynecol Obstet. 2013; 287(1):43–6. https://doi.org/10.1007/s00404-012-2523-z PMID: 22930148

23. Agrawal S, Das V, Verma V, Agarwal A, Pandey A, Jain V. Evaluation of medium dose versus standard Pritchard regime of magnesium sulfate in the management of eclampsia in developing nation. Int J Gynaecol Obstet. 2015; 131(Suppl 5):E183.

24. Bain E, Middleton P, Yealland L, Ashwood P, Crowther C. Maternal adverse effects with different loading infusion rates of antenatal magnesium sulphate for preterm fetal neuroprotection: the IRIS randomised trial. Br J Obstet Gynaecol. 2014; 121(5):595–603.

25. Begum M, Begum A, Quadir E. Loading dose versus standard regime of magnesium sulfate in the management of eclampsia: a randomized trial. J Obstet Gynaecol Res. 2002; 28(3):154–9. https://doi.org/10.1046/j.1341-8076.2002.00029.x PMID: 12214831

26. Behrad B, Moossavifar N, Motahedzadeh M, Esmaili H, Moghtadei P. A prospective, randomized, controlled trial of high and low doses of magnesium sulfate for acute tocolysis. Acta Med Iran. 2003; 41(2):126–31.

27. Bhattarchjee N, Saha S, Ganguly R, Patra K, Shali B, Das N, et al. A randomised comparative study between low-dose intravenous magnesium sulphate and standard intramuscular regimen for the treatment of eclampsia. J Obstet Gynaecol. 2011; 31(4):298–303. https://doi.org/10.3109/01443615.2010.549972 PMID: 21534749
28. Blackwell S, Hallak M, Hassan S, Berry S, Russell E, Sorokin Y. The effects of intrapartum magnesium sulfate therapy on fetal serum interleukin-1β, interleukin-6, and tumor necrosis factor-α at delivery: a randomized, placebo-controlled trial. Am J Obstet Gynecol. 2001; 184(7):1320–4. https://doi.org/10.1067/mob.2001.115745 PMID: 11408847

29. Chama C, Geidam A, Bako B, Mairega A, Attewahami A. A shortened versus standard matched postpartum magnesium sulphate regimen in the treatment of eclampsia: a randomised controlled trial. Afr J Reprod Health. 2013; 17(3):131–6. PMID: 24069775

30. Chen F-P, Chang S-D, Chu K-K. Expectant management in severe preeclampsia: does magnesium sulfate prevent the development of eclampsia? Acta Obstet Gynecol Scand. 1995; 74(3):182–5.

31. Chissell S, Botha J, Moodley J, McFadyen L. Intravenous and intramuscular magnesium sulphate regimens in severe pre-eclampsia. S Afr Med J. 1994; 84(9):607–10. PMID: 7839282

32. Coetzee E, Dommisse J, Botha J, Moodley J, McFadyen L. Intravenous and intramuscular magnesium sulphate regimens in severe pre-eclampsia. S Afr Med J. 1994; 84(9):607–10. PMID: 7839282

33. Crowther C, Hiller J, Doyle L, Haslam R, Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. A randomised controlled trial. JAMA. 2003; 290(20):2669–76. https://doi.org/10.1001/jama.290.20.2669 PMID: 1465308

34. Easterling T, Hebert M, Bracken H, Darwish E, Ramadan MC, Shaarawy S, et al. A randomized trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with serial intravenous boluses versus a continuous intravenous infusion, BMC Pregnancy Childbirth. 2018; 18(1):290. https://doi.org/10.1186/s12884-018-1919-6 PMID: 29976161

35. Fox M, Allbert J, McCaul J, Martin R, McLaughlin B, Morrison J. Neonatal morbidity between 34 and 37 weeks’ gestation. Obstet Gynecol Surv. 1993; 49(4):242–3.

36. How HY C C, Cook VD, Miles DE, Spinnato JA. Preterm premature rupture of membranes: aggressive tocolysis versus expectant management. J Matern Fetal Med. 1998; 7(1):8–12. https://doi.org/10.1002/sjc.128804-018-1919-6 PMID: 9502662

37. Keeapanseril A, Maurya DK, Manikandan K, Suriya YJ, Habeebullah S, Raghavan SS. Prophylactic magnesium sulphate in prevention of eclampsia in women with severe pre-eclampsia: randomised controlled trial (PiPES trial). J Obstet Gynaecol. 2018; 38(3):305–9. https://doi.org/10.1080/01443615.2017.1351931 PMID: 28974124

38. Lewis DF, Bergstedt S, Edwards MS, Burlison S, Gallaspy JW, Brooks GG, Adair CD. Successful magnesium sulfate tocolysis: is “weaning” the drug necessary? Am J Obstet Gynecol. 2002; 187(4):742–5. https://doi.org/10.1067/s0002-9378(07)70261-6 PMID: 9369812

39. Livingston J, Livingston L, Ramsey R, Mabie B, Sibai B. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2003; 101(2):217–20. https://doi.org/10.1016/s0029-7844(02)03053-3 PMID: 12576241

40. Malapaka S, Ballal P. Low-dose magnesium sulphate versus Pritchard regimen for the treatment of eclampsia and imminent eclampsia. Int J Gynaecol Obstet. 2011; 115(1):70–2. https://doi.org/10.1016/j.ijgo.2011.05.013 PMID: 21798530

41. Marret S, Marmeau L, Zupan-Simunek V, Euirin D, Leveque C, Hellot M-F, et al. Magnesium sulphate given before very preterm birth to protect infant brain: the randomised controlled PREMAG trial. Br J Obstet Gynaecol. 2007; 114(3):310–8.

42. Mirzamoradi M, Behnam M, Jahan T, Saleh-Gargari S. Does magnesium sulfate delay the active phase of labor in women with premature rupture of membranes? A randomized controlled trial. Taiwan J Obstet Gynecol. 2014; 53(3):300–12. https://doi.org/10.1016/j.tjog.2013.06.014 PMID: 25286782
47. Mittendorf R, Dambrosia J, Pryde P, Lee K-S, Gianopoulois J, Besinger R, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol. 2002; 186(6):1111–8. https://doi.org/10.1067/mob.2002.123544 PMID: 12066082

48. Moodley J, Moodley V. Prophylactic anticonvulsant therapy in hypertensive crises of pregnancy—the need for a large, randomized trial. Hypertens Pregnancy. 1994; 13(3):245–52.

49. Mundie S, Regi A, Easterling T, Biswas B, Bracken H, Khadkar V, et al. Treatment approaches for preeclampsia in low-resource settings: a randomized trial of the Springfusor pump for delivery of magnesium sulfate. Pregnancy Hypertens. 2012; 2(1):32–8. https://doi.org/10.1016/j.preghy.2011.09.002 PMID: 26104987

50. Orji E, Ogoke G, Fasubaa O. Efficacy of a single loading dose of magnesium sulphate versus the standard Pritchard regimen in the management of severe preeclampsia in an African population. Int J Gynaecol Obstet. 2012; 119(S3):S447.

51. Parashi S, Bordbar A, Mahmoody Y, Jafari M. The survey of magnesium sulfate in prevention of intraventricular haemorrhage in premature infants: a randomized clinical trial. Shiraz E Med J. 2017; 18(11):e16779.

52. Pascoal ACF, Katz L, Pinto MH, Santos CA, Braga LCO, Maia SB, et al. Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: a randomized clinical trial. Medicine (Baltimore). 2019; 98(32):e16779.

53. Rimal S, Rijal P, Bhatt R, Thapa K. Loading dose only versus standard dose magnesium sulfate seizure prophylaxis in severe pre-eclamptic women. J Nepal Med Assoc. 2017; 56(208):388–94.

54. Rouse D, Hirtz D, Thom E, Varner M, Spong C, Mercer B, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008; 359(9):895–905. https://doi.org/10.1056/NEJMoa0801187 PMID: 18753646

55. Shilva, Saha S, Kalra J, Prasad R. Safety and efficacy of low-dose intramuscular magnesium sulphate (MgSO4) compared to intravenous regimen for treatment of eclampsia J Obstet Gynaecol Res. 2017; 4(10):1543–9.

56. Shreya M, Krishna L, Shailaja N, Bhat B. Evaluation of single dose magnesium sulphate and Pritchard regimen in the treatment of eclampsia—a comparative study. Biomedicine. 2014; 34(2):252–6.

57. Singh S, Behera A. Eclampsia in Eastern India: incidence, demographic profile and response to three different anticonvulsant regimes of magnesium sulphate. Internet J Gynecol Obstet. 2011; 15(2):1–7.

58. Tangmanowutthiku S, Champawong R, Songthamwat S, Songthamwat M. Comparison of magnesium sulphate protocols by weight-adjusted versus two grams per hour for preventing convulsion in preeclampsia: a randomised controlled trial. J Clin Diagn Res. 2019; 13(2):QC01–4.

59. Terrone D, Rinehart B, Kimmel E, May W, Larmon J, Morrison J. A prospective, randomized, controlled trial of high and low maintenance doses of magnesium sulfate for acute tocolysis. Am J Obstet Gynecol. 2000; 182(6):1477–82. https://doi.org/10.1067/mob.2000.107334 PMID: 10871468

60. Willtin A, Friedman S, Sibai B. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1997; 176(3):623–7. https://doi.org/10.1016/s0002-9378(97)70558-1 PMID: 9077617

61. Adama-Hondegla AB, Lawson-Evi K, Bassowa A, Modji S, Egbia KF, Akpadza K. Perinatal mortality risk factors of infants born from eclamptic mothers at Tokoin Teaching Hospital of Lome. Pak J Med Sci. 2013; 13(5):391–5.

62. Alexander JM, McIntire DD, Leveno KJ, Cunningham FG. Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension. Obstet Gynecol. 2008; 108(4):826–32. https://doi.org/10.1097/AOG.0000235721.88349.80 PMID: 17012442

63. Alston MJ, Alexandrovic K, Stiglich N, Metz TD. Discontinuation of tocolytics for preterm labor in an academic safety net hospital: impact on the duration of betamethasone exposure. J Reprod Med. 2016; 61(2):109–13.

64. Ambadkar A, Prasad M, Chauhan AR. Neonatal effects of maternal magnesium sulphate in late pre-term and term pregnancies. J Obstet Gynaecol India. 2019; 69(1):25–30. https://doi.org/10.1016/s13224-017-1074-4 PMID: 30814806

65. Bajaj M, Nataraman G, Shankaran S, Wyckoff M, Laptook AR, Bell EF, et al. Delivery room resuscitation and short-term outcomes in moderately preterm infants. J Pediatr. 2018; 195:33–8e2. https://doi.org/10.1016/j.jpeds.2017.11.039 PMID: 29306493
67. Basu SK, Chickajur V, Lopez V, Bhutada A, Pagala M, Rastogi S. Immediate clinical outcomes in preterm neonates receiving antenatal magnesium for neuroprotection. J Perinat Med. 2012; 40 (2):185–9.

68. Belden MK, Gnadt S, Ebert A. Effects of maternal magnesium sulfate treatment on neonatal feeding tolerance. J Pediatr Pharmacol Ther. 2017; 22(2):112–7.

69. Bertello Greco M, Barrón B, Rigo D, McCormick Cook A, Pajón Scocco J, Novoa P, et al. Maternal and neonatal safety with the use of magnesium sulfate in preeclampsia. Kidney Int Rep. 2019; 4(7): S146.

70. Black B, Holditch-Davis D, Schwartz T, Scher MS. Effects of antenatal magnesium sulfate and corticosteroid therapy on sleep states of preterm infants. Res Nurs Health. 2006; 29(4):269–80. https://doi.org/10.1002/nur.20141 PMID: 16847907

71. Blackwell SC, Redman ME, Whitty JE, Refuerzo JS, Berry SM, Sorokin Y, et al. The effect of intrapartum magnesium sulfate therapy on fetal cardiac troponin I levels at delivery. J Matern Fetal Neonatal Med. 2002; 12(5):327–31. https://doi.org/10.1080/jmfn.12.5.327.331 PMID: 12607765

72. Bonta BW, Chin TK, DeVoe WM. Maternal intravenous MgSO4 administration and its effects on neonatal respiratory function and risk of development of hemodynamically significant patent ductus arteriosus shunts during the initial 72 hours of life. J Investig Med. 2000; 48(1):107A.

73. Boyle A, Greer K, Caballero A, Norton T, Kate P, Ferguson J, et al. Neonatal outcomes in obese women undergoing cesarean delivery for fetal heart rate tracing abnormalities. Am J Obstet Gynecol. 2018; 218(1):S335.

74. Bozkurt O, Eras Z, Canpolat FE, Oguz SS, Uras N, Dilmen U. Antenatal magnesium sulfate and neurodevelopmental outcome of preterm infants born to preeclamptic mothers. J Matern Fetal Neonatal Med. 2016; 29(7):1101–4. https://doi.org/10.3109/14767058.2015.1035641 PMID: 25893546

75. Brazy JE, Grimm JK, Little VA. Neonatal manifestations of severe maternal hypertension occurring before the thirty-sixth week of pregnancy. J Pediatr. 1982; 100(2):265–71. https://doi.org/10.1016/s0022-3476(82)80653-7 PMID: 7057337

76. Brookfield K, Su F, Drover D, Adelus M, Lyell D, Carvalho B. Umbilical cord magnesium levels and neonatal resuscitation in infants exposed to magnesium sulfate. Am J Obstet Gynecol. 2015; 212(1 Suppl):S395–6.

77. Brookfield K, O’Malley K, Yeaton-Massey A, Butwick A. Does magnesium sulfate exposure attenuate the effete of steroids administered for fetal lung maturation? Am J Obstet Gynecol. 2016; 1(Suppl): S89.

78. Brown BE, Vincer M, Acott P, El-Naggar W, O’Connell C, Kajetanowicz A. Systemic hypertension in preterm infants—a population-based study. Paediatr Child Health. 2019; 24(Suppl 2):e47–8.

79. Canterino JC, Verma UL, Visintainer PF, Figueroa R, Klein SA, Tejani NA. Maternal magnesium sulfate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. Obstet Gynecol. 1999; 93(3):396–402. https://doi.org/10.1016/s0022-3476(98)00455-4 PMID: 10074897

80. Cawyer CR. The association of magnesium sulfate with maternal morbidity when used for preeclampsia without severe features. Am J Obstet Gynecol. 2019; 220(1):S292–3.

81. Cho GJ, Lee JE, Hong HR, Hong SC, Hong YS, Kim HJ, et al. Maternal magnesium sulfate treatment is not associated with serum calcium levels of preterm neonate. Am J Obstet Gynecol. 2014; 210(1 Suppl):S356.

82. Chowdhury JR, Chaudhuri S, Bhattacharyya N, Biswas PK, Panapila M. Comparison of intramuscular magnesium sulfate with low dose intravenous magnesium sulfate regimen for treatment of eclampsia. J Obstet Gynaecol Res. 2009; 35(1):119–25. https://doi.org/10.1111/j.1447-0766.2008.00842.x PMID: 19215558

83. Chun E-H, Do S-H, Shin H-J, Na H-S, Hwang J-W. Effects of magnesium sulfate on the labor duration and neonatal outcome in parturients with preeclampsia. Anesth Pain Med. 2014; 9(2):128–33.

84. Cuff RD, Sullivan SA, Chang EY. Impact of dosing schedule on uptake of neuroprotective magnesium sulfate. J Matern Fetal Neonatal Med. 2018 Sep 19. https://doi.org/10.1080/14767058.2018.1513482 PMID: 30122071

85. Das M, Chaudhuri PR, Mondal BC, Mitra S, Bandyopadhyay D, Pramanik S. Assessment of serum magnesium levels and its outcome in neonates of eclamptic mothers treated with low-dose magnesium sulfate regimen. Indian J Pharmacol. 2015; 47(5):502–8. https://doi.org/10.4103/0253-7613.165183 PMID: 2660638

86. De Jesus L, Sood B, Shankaran S, Kendrick D, Das A, Bell E, et al. Antenatal magnesium sulfate exposure and acute cardiorespiratory events in preterm infants. Am J Obstet Gynecol. 2015; 212(1):94.e1–7.
Garcia Alonso L, Pumarada Priet M, Gonzalez Colmenero E, Concheiro Guisan A, Suarez Albo M, Gano D, Ho ML, Partridge JC, Glass HC, Xu D, Barkovich AJ, et al. Antenatal exposure to magnesium sulfate in utero decreases the risk of cerebral palsy. J Perinatol. 2007; 27(3):154–7. https://doi.org/10.1038/sj.jp.7211663 PMID: 17314984

Ghidini A, Espada RA, Spong CY. Does exposure to magnesium sulfate in utero decrease the risk of cerebral palsy in very low birth weight infants. J Investig Med. 1998; 46(1):175A.

del Moral T, Gonzalez-Quintero VH, Claure N, Vanbuskirk S, Bancalari E. Antenatal exposure to magnesium sulfate and the incidence of patent ductus arteriosus in extremely low birth weight infants. J Perinatol. 2007; 27(3):154–7. https://doi.org/10.1038/sj.jp.7211663 PMID: 17314984

del Valle GM, Bister GL, Lynch LA, Cummings JJ. Prenatal magnesium sulfate exposure and the incidence of cerebral palsy in very low birth weight infants. J Investig Med. 1998; 46(1):175A.

Derks JB, Sol CM, Van Leeuwen J, Keuken M, Mulder EJ, De Vries LS, et al. Antenatal magnesium sulfate for neuroprotection reduces punctate white matter lesions at 30 weeks MRI in the human neonate. Reprod Sci. 2016; 23(Suppl 1):273A.

Downey LC, Cotten CM, Hornik CP, Laughon MM, Tolia VN, Clark RH, et al. Association of in utero magnesium exposure and spontaneous intestinal perforations in extremely low birth weight infants. J Perinatol. 2017; 37(6):641–4. https://doi.org/10.1038/jp.2016.274 PMID: 28125094

Drassnower D, Obican S, Levin H, Gyamfi-Bannerman C. Immediate neonatal outcomes in infants exposed to magnesium sulfate at the time of delivery. Am J Obstet Gynecol. 2015; 212(1 Suppl):S90.

Duffy CR, Odibo AO, Rohei KA, Macones GA, Cahill AG. Effect of magnesium sulfate on fetal heart rate patterns in the second stage of labor. Obstet Gynecol. 2012; 119(6):1129–36. https://doi.org/10.1097/AOG.0b013e318257181e PMID: 22617576

Edwards J, Edwards L, Swamy G, Grotegut C. Magnesium sulfate for neuroprotection in the setting of chorioamnionitis. J Matern Fetal Neonatal Med. 2018; 31(9):1156–60. https://doi.org/10.1080/14767105.2017.1311312 PMID: 28395549

Elimian A, Verma R, Ogburn P, Wiencek V, Spitzer A, Quirk JG. Magnesium sulfate and neonatal outcomes of preterm neonates. J Matern Fetal Neonatal Med. 2002; 12(2):118–22. https://doi.org/10.1080/jmf.12.2.118.122 PMID: 12420842

Elliott J, Garite T, Clark R, Combs A. Perinatal effect of magnesium sulfate administered for tocolysis. Am J Obstet Gynecol. 2003; 189(6 Suppl):S63.

Farkouh LJ, Thorp JA, Jones PG, Clark RH, Knox GE. Antenatal magnesium exposure and neonatal demise. Am J Obstet Gynecol. 2001; 185(4):869–72. https://doi.org/10.1067/mob.2001.117362 PMID: 11641668

FineSmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, et al. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. Am J Perinatol. 1997; 14(5):303–7. https://doi.org/10.1055/s-2007-994478 PMID: 9259949

Gano D, Ho ML, Partridge JC, Glass HC, Xu D, Barkovich AJ, et al. Antenatal exposure to magnesium sulfate is associated with reduced cerebellar hemorrhage in preterm newborns. J Pediatr. 2016; 178:68–74. https://doi.org/10.1016/j.jpeds.2016.06.053 PMID: 27453378

Garcia Alonso L, Pumarada Priet M, Gonzalez Colmenero E, Concheiro Guisan A, Suarez Albo M, Duran Fernandez-Feijoo C, et al. Prenatal therapy with magnesium sulfate and its correlation with neonatal serum magnesium concentration. Am J Perinatol. 2018; 35(2):170–6. https://doi.org/10.1055/s-0037-1606358 PMID: 28854447

Gasparyan A. [Neurosonographical characteristics of dysmature infants depending on conducted neuroprotection.] Georgian Med News. 2017;(268–9):72–5.

Ghidini A, Espada RA, Spong CY. Does exposure to magnesium sulfate in utero decrease the risk of necrotizing enterocolitis in premature infants? Acta Obstet Gynecol Scand. 2001; 80(2):126–9. PMID: 1167206

Gibbins KJ, Brownin g KR, Lopes VV, Anderson BL, Rouse DJ. Evaluation of the clinical use of magnesium sulfate for cerebral palsy prevention. Obstet Gynecol. 2013; 121(2 Pt 1):235–40. https://doi.org/10.1097/AOG.0b013e31827c5c8 PMID: 23344271

Girsen AI, Greenberg MB, El-Sayed YY, Lee H, Carvalho B, Lyell DJ. Magnesium sulfate exposure and neonatal intensive care unit admission at term. J Perinatol. 2015; 35(3):181–5. https://doi.org/10.1097/jp.2014.184 PMID: 25321647

Gonzalez-Quintero VH, Tolaymat L, Claire N, Vanbuskirk S, Siman D, del Moral T, et al. Survival rate in neonates exposed to magnesium sulfate. J Perinat Med. 2001; 29(Suppl 1):20.
108. Greenberg MB, Penn AA, Thomas LJ, El-Sayed YY, Caughey AB, Lyell DJ. Neonatal medical admission in a term and late-preterm cohort exposed to magnesium sulfate. Am J Obstet Gynecol. 2011; 204(6):515.e1–7.

109. Greenberg MB, Penn AA, Whitaker KR, Kogut EA, El-Sayed YY, Caughey AB, et al. Effect of magnesium sulfate exposure on term neonates. J Perinatol. 2013; 33(3):188–93. https://doi.org/10.1038/jp.2012.95 PMID: 22836873

110. Grether JK, Hoogstrate J, Selvin S, Nelson KB. Magnesium sulfate tocolysis and risk of neonatal death. Am J Obstet Gynecol. 1998; 178(1 Pt 1):1–6. https://doi.org/10.1016/s0002-9378(98)70617-9 PMID: 9465794

111. Grimblly C, Rosolowsky E, Aziz K, O'Reilly M, Cheung PY, Schmolzer G. New baby jitters: novel characterization of the incidence and risk factors for neonatal hypoglycemia in the premature infant <33 weeks. Paediatr Child Health. 2015; 20(5):e86.

112. Gulcan H, Gungor S, Tiker F, Kilicdag H. Effect of perinatal factors on time of first stool passage in preterm newborns: an open, prospective study. Curr Ther Res Clin Exp. 2006; 67(3):214–25. https://doi.org/10.1016/j.curtheres.2006.06.002 PMID: 24678097

113. Gursoy T, Imamoglu EY, Ovali F, Karatekin G. Effects of antenatal magnesium exposure on intestinal blood flow and outcome in preterm neonates. Am J Perinatol. 2015; 32(11):1064–9. https://doi.org/10.1055/s-0035-1548541 PMID: 25825964

114. Havranek T, Ashmeade TL, Afanador M, Carver JD. Effects of maternal magnesium sulfate administration on intestinal blood flow velocity in preterm neonates. Neonatology. 2011; 100(1):44–9. https://doi.org/10.1159/00019049 PMID: 21212694

115. Hechtman J, Blackwell S, Moldenhauer J, Refuerzo J, Hassan S, Berry S, et al. Lack of association of neonatal mortality and exposure to tocolytic magnesium. Am J Obstet Gynecol. 2002; 187(Suppl 1):S124.

116. Holcomb WL, Shackelford GD, Petrie RH. Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991; 78(4):611–4. PMID: 1923163

117. Hong JY, Kim Y-M, Hong JY, Seo M-r, Chae J, Sung J-H, et al. Does antenatal magnesium sulfate exposure increase the risk of necrotizing enterocolitis in preterm neonates? Am J Obstet Gynecol. 2019; 220(1):S327.

118. Igarashi H, Honma Y, Suwa K, Momi M, Yanagisawa M. The clinical effects of hypermagnesemia on preterm infants of mothers treated with magnesium sulfate for tocolysis. Acta Neonatol Japon. 1995; 31(2):388–93.

119. Imamoglu EY, Gursoy T, Karatekin G, Ovali F. Effects of antenatal magnesium sulfate treatment on cerebral blood flow velocities in preterm neonates. J Perinatol. 2014; 34(3):192–6. https://doi.org/10.1038/jp.2013.182 PMID: 24480905

120. James AT, Corcoran JD, Hayes B, Franklin O, El-Khuffash A. The effect of antenatal magnesium sulfate on left ventricular afterload and myocardial function measured using deformation and rotational mechanics imaging. J Perinatol. 2015; 35(11):913–8. https://doi.org/10.1038/jp.2015.104 PMID: 26291779

121. Jazayeri A, Jazayeri MK, Sutkin G. Tocolysis does not improve neonatal outcome in patients with preterm rupture of membranes. Am J Perinatol. 2003; 20(4):189–93. https://doi.org/10.1055/s-2003-40606 PMID: 12874729

122. Jeanneteau P, Bouet PE, Baison AL, Courtay V, Gascoin-Lachambre G, Gillard P, et al. Evaluation of the clinical use of magnesium sulfate for cerebral palsy prevention. J Matern Fetal Neonatal Med. 2014; 27(Suppl 1):377–8.

123. Jones CW, Petrashek K, Wenzlaff M, Simpson P, Pan AY. Prenatal magnesium sulfate and time to first stool in late preterm infants. Obstet Gynecol. 2018; 131(Suppl 1):160S.

124. Jung EJ, Byun JM, Kim YN, Lee KB, Sung MS, Kim KT, et al. Antenatal magnesium sulfate for both tocolysis and fetal neuroprotection in premature rupture of the membranes before 32 weeks’ gestation. J Matern Fetal Neonatal Med. 2018; 31(11):1431–41. https://doi.org/10.1080/14767058.2017.1317743 PMID: 28391733

125. Kamilya G, Bharracharya SK, Mukherji J. Changing trends in the management of eclampsia from a teaching hospital. J Indian Med Assoc. 2005; 103(3):132,134–5.

126. Kamyar M, Bardsley T, Korgenski K, Clark E. Magnesium sulfate and the extremely low birth weight neonate. Am J Obstet Gynecol. 2015; 212(1 Suppl):S362–3.

127. Kamyar M, Bardsley T, Korgenski K, Clark EAS. Association of antenatal magnesium sulfate with neonatal morbidity and mortality in very preterm infants. Reprod Sci. 2015; 22(Suppl 1):144A.
129. Kamyar M, Clark EA, Yoder BA, Varner MW, Manuck TA. Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates<28 weeks gestation. AJP Rep. 2016; 6(1):e148–54. https://doi.org/10.1055/s-0036-1581059 PMID: 27054046

130. Kamyar M, Manuck TA, Stoddard GJ, Varner MW, Clark EAS. Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth. Br J Obstet Gynaecol. 2016; 123(7):1161–6. PMID: 27167015

131. Kamyar M, Varner M, Clark E. Magnesium sulfate neuroprophylaxis and the effect of infant sex. Am J Obstet Gynecol. 2015; 212(1 Suppl):S144.

132. Katayama Y, Minami H, Enomoto M, Takano T, Hayashi S, Lee YK. Antenatal magnesium sulfate and the postnatal response of the ductus arteriosus to indomethacin in extremely preterm neonates. J Perinatol. 2011; 31(1):21–4. https://doi.org/10.1038/jp.2010.62 PMID: 20505743

133. Kelly MJ, Viscardi RM. Effects of maternal magnesium sulfate on preterm newborns. Pediatr Res. 1992; 31(4 Pt 2):207A. PMID: 13172709

134. Khodapanah andeh F, Khosravi N, Larijani T. Risk factors for intraventricular hemorrhage in very low birth weight infants in Tehran, Iran. Turk J Pediatr. 2008; 50(3):247–52. PMID: 18773670

135. Kuban KC, Leviton A, Pagano M, Fenton T, Strassfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. J Child Neurol. 1992; 7(1):70–6. https://doi.org/10.1177/088307389200700113 PMID: 15521562

136. Koksal N, Baytan B, Bayram Y, Nacarkucuk E. Risk factors for intraventricular haemorrhage in very low birth weight infants. Indian J Pediatr. 2002; 69(7):561–4. https://doi.org/10.1007/bf02722677 PMID: 12137693

137. Kuban KC, Leviton A, Park EA, Fenton T, Strassfeld R, Wolff M. Maternal magnesium sulfate neuroprophylaxis and the effect of infant sex. Am J Obstet Gynecol. 2015; 212(1 Suppl):S144.

138. Kohn DH, Cifra CL, Agthe AG, Sun CC, Viscardi RM. Antenatal factors modulate hearing screen failure risk in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2016; 101(1):F56–61. https://doi.org/10.1136/archdischild-2014-307843 PMID: 26195624

139. Lipsitz PJ. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics. 1971; 47(3):501–9. PMID: 5547870

140. Lloreda-Garcia JM, Lorente-Nicolás A, Bermejo-Costa F, Martínez-Uriarte J, López-Pérez R. Necesidad de reanimación en prematuros menores de 32 semanas expuestos a sulfato de magnesio para neuroprotección fetal. Rev Chil Pediatr. 2016; 67(4):261–7.

141. Martin D, Gonzalez JL, Gardner MO, Izquierdo LA, Tobey K, Curet LB. Incidence of intraventricular hemorrhage in neonates under 32 weeks of gestation delivered to mothers with severe pre-eclampsia. Prenat Neonatal Med. 1998; 3(2):250–4. PMID: 9286718

142. Matsuda Y, Maeda Y, Ilo M, Sakamoto H, Masaoka N, Takada M, et al. Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997; 44(2):82–8. https://doi.org/10.1159/000291492 PMID: 9286718

143. McGuinness GA, Weinstein MM, Cruikshank DP, Pitkin RM. Effects of magnesium sulfate treatment on neonatal bone abnormalities. II. Neonatal outcomes. Obstet Gynecol. 1980; 56(5):595–600. PMID: 7432730

144. McPherson JA, Rouse DJ, Grobman WA, Palatnik A, Stamilo DM. Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstet Gynecol. 2014; 124(4):749–55. https://doi.org/10.1097/AOG.0000000000000467 PMID: 25196275

145. Mikhail M, Bronson C, Zhang L, Curran M, Rodriguez H, Bhakta KY. Lack of evidence for time or dose relationship between antenatal magnesium sulfate and intestinal injury in extremely preterm neonates. Neonatology. 2019; 115(4):371–8. https://doi.org/10.1159/000497412 PMID: 30955040

146. Mikhael M, Bronson C, Zhang L, Curran M, Rodriguez H, Bhakta KY. Lack of evidence for time or dose relationship between antenatal magnesium sulfate and intestinal injury in extremely preterm neonates. Neonatology. 2018; 115(4):371–8. https://doi.org/10.1159/000497412 PMID: 30955040

147. Mitani M, Matsuda Y, Shimada E. Short- and long-term outcomes in babies born after antenatal magnesium treatment. J Obstet Gynaecol Res. 2011; 37(11):1609–14. https://doi.org/10.1111/j.1447-0756.2011.01583.x PMID: 21733038
151. Mittendorf R, Besinger R, Santillan M, Gianopoulos J. When used in the circumstance of preterm labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MgSO4) on the developing human brain? Am J Obstet Gynecol. 2005; 193(6):S65.

152. Mittendorf R, Pryde P, Gianopoulos J, Besinger R, Lee K-S. Thalamostriate vasculopathy in the neonate is associated with antenatal exposures to tocolytic MgSO4. Am J Obstet Gynecol. 2009; 201(6): S79.

153. Morag I, Okrent AL, Strauss T, Starets-Chacham O, Kuint J, Simchen MJ, et al. Early neonatal morbidities and associated modifiable and non-modifiable risk factors in a cohort of infants born at 34–35 weeks of gestation. J Matern Fetal Neonatal Med. 2015; 28(8):876–82. https://doi.org/10.3109/14767058.2014.938043 PMID: 24962498

154. Morag I, Yakubovich D, Stern O, Siman-Tov M, Schuschan-Eisen I, Strauss T, et al. Short-term morbidities and neurodevelopmental outcomes in preterm infants exposed to magnesium sulphate treatment. J Paediatr Child Health. 2016; 52(4):397–401. https://doi.org/10.1111/jpc.13103 PMID: 27145502

155. Moschos E, Magee K. Does magnesium sulfate exposure decrease the incidence of necrotizing enterocolitis? Am J Obstet Gynecol. 2001; 185(6 Suppl):S148.

156. Murata Y, Itakura A, Matsuzawa K, Okumura A, Wakai K, Mizutani S. Possible antenatal and perinatal related factors in development of cystic periventricular leukomalacia. Brain Dev. 2005; 27(1):17–21. https://doi.org/10.1016/j.braindev.2004.02.011 PMID: 15626536

157. Nakamura Y, Ibara S, Ikenoue T. Effect of maternally administered magnesium sulphate on the neonate. J Perinatol. 1991; 19(Suppl 2):136.

158. Narasimhulu D, Brown A, Egbert NM, Rojas M, Haberman S, Bhutada A, et al. Maternal magnesium therapy, neonatal serum magnesium concentration and immediate neonatal outcomes. J Perinatol. 2017; 37(12):1297–303. https://doi.org/10.1038/jp.2017.132 PMID: 28981078

159. Nassar AH, Sakhel K, Maarouf H, Nassar GR, Usta IM. Adverse maternal and neonatal outcomes of prolonged course of magnesium sulfate tocolysis. Acta Obstet Gynecol Scand. 2006; 85(9):1099–103. https://doi.org/10.1080/0001634060756898 PMID: 16929415

160. Nelson KB, Grether JK. Can magnesium sulphate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics. 1995; 95(2):263–9. PMID: 7838646

161. Nunes RD, Schultz FD, Traebert JL. Association between the use of magnesium sulphate as a neuroprotective drug in preterm birth. J Perinatol. 1991; 19(Suppl 2):136.

162. O Reilly E, Rogers EL, Hayes B. Effects of magnesium sulphate on respiratory function in the preterm infant. J Matern Fetal Neonatal Med. 2018; 31(14):1900–5. https://doi.org/10.1080/14767058.2017.132033 PMID: 28521581

163. O Reilly E, Rogers EL, Hayes B. Effects of magnesium sulphate on respiratory function in the preterm infants who received magnesium sulphate prophylaxis at delivery. Ir J Med Sci. 2016; 185:S277–8.

164. O Reilly E, Rogers EL, Hayes B. Effects of magnesium sulphate on respiratory function in the preterm infants who received magnesium sulphate prophylaxis at delivery. Ir J Med Sci. 2016; 185:S277–8.

165. Okusanya BO, Garba KK, Ibrahim HM. The efficacy of 10 gram intramuscular loading dose of MgSO4 in severe preeclampsia/eclampsia at a tertiary referral centre in Northwest Nigeria. Niger Postgrad Med J. 2012; 19(3):143–8. PMID: 23064169

166. Özlı F, Hacıoğlu C, Büyükurt S, Yapıcıoğlu H, Satar M. Changes on preterm morbidities with antenatal magnesium. Cukurova Med J. 2019; 44(2):502–8. https://doi.org/10.17826/cumj.444238 PMID: 31089257

167. Palatnik A, Liu LY, Lee A, Yee LM. Predictors of early-onset neonatal sepsis or death among newborns born at <32 weeks of gestation. J Perinatol. 2019; 39(7):949–55. https://doi.org/10.1038/s41372-019-0395-9 PMID: 31089257

168. Paneth N, Jetton J, Pinto-Martín J, Susser M. Magnesium sulfate in labor, is there a paradoxical effect of varying exposures to magnesium sulfate (MgSO4) on the developing human brain? Am J Obstet Gynecol. 2005; 193(6):S65.

169. Pelikan J, Fernandez C, Gee J, Leveno K, Risser R. Magnesium sulphate (Mg) administered to mothers with pregnancy-induced hypertension (PIH) is associated with a reduction in periventricular-intraventricular hemorrhage (PV-I VH). Pediatr Res. 1995; 37(4 Pt 2):231A.

170. Qasim A, Jain S, Dasa Gupta S. Does antenatal magnesium sulfate increase the likelihood of a hemodynamically significant patent ductus arteriosus in neonates? J Investig Med. 2017; 65(2):547–8.

171. Rantonen T, Kaapa P, Gronlund J, Ekblad U, Helenius H, Kero P, et al. Maternal magnesium sulphate treatment is associated with reduced brain-blood flow perfusion in preterm infants. Crit Care Med. 2001; 29(7):1460–5. https://doi.org/10.1097/00003246-200107000-00026 PMID: 11445708
172. Rasch DK, Huber PA, Richardson CJ, L'Hommedieu CS, Nelson TE, Reddi R. Neurobehavioral effects of neonatal hypermagnesemia. J Pediatr. 1982; 100(2):272–6. https://doi.org/10.1016/s0022-3476(82)80654-9 PMID: 7199083

173. Rattray BN, Kraus DM, Drinker LR, Goldberg RN, Tanaka DT, Cotteen CM. Antenatal magnesium sulfate and spontaneous intestinal perforation in infants less than 25 weeks gestation. J Perinatol. 2014; 34(11):819–22. https://doi.org/10.1038/jp.2014.106 PMID: 24901451

174. Raul M, Sevil E, Ebru C, Yavuz S, Cemil C. Antenatal magnesium sulfate use for fetal neuroprotection: experience from a tertiary care hospital in Turkey. Biomed Res. 2017; 28(4):1749–54.

175. Rhee E, Beiswenger T, Ogueliojer CE, James AH. The effects of magnesium sulfate on maternal and fetal platelet aggregation. J Matern Fetal Neonatal Med. 2012; 25(5):478-83. https://doi.org/10.3109/14767058.2011.584087 PMID: 21762000

176. Riaz M, Porat R, Brodsky NL, Hurt H. The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998; 18(6 Pt 1):449–54. PMID: 9848759

177. Rizzolo A, Shah PS, Boucorian I, Lemyre B, Bertelle V, Pelausa E, et al. Cumulative effect of evidence-based practices on outcomes of preterm infants born at <29 weeks gestational age. Am J Obstet Gynecol. 2019 Sept 6. https://doi.org/10.1016/j.ajog.2019.08.058 PMID: 31499055

178. Sakae C, Sato Y, Kanbayashi S, Taga A, Emoto I, Maruyama S, et al. Introduction of management protocol for early-onset severe pre-eclampsia. J Obstet Gynaecol Res. 2017; 43(4):644–52. https://doi.org/10.1111/jog.13265 PMID: 28150368

179. Sahin H, Akay AF, Bircan MK, Gocmen A, Bircan Z. The first micturition times of the newborns whose mothers were treated with magnesium sulfate. Int Urol Nephrol. 2001; 32(4):651–3. https://doi.org/10.1023/a:1014405824678 PMID: 11989558

180. Salafia CM, Minior VK, Rosenkrantz TS, Pezzullo JC, Popek EJ, Cusick W, et al. Maternal, placental, and neonatal associations with early germinal matrix/intraventricular hemorrhage in infants born before 32 weeks gestation. Am J Obstet Gynecol. 1998; 178(1 Pt 1):178–82. https://doi.org/10.1016/s0002-9378(98)00893-0 PMID: 9194621

181. Shokry M, Elsedfy GO, Bassiouny MM, Anmin M, Abozid H. Effects of antenatal magnesium sulfate therapy on cerebral and systemic hemodynamics in preterm newborns. Acta Obstet Gynecol Scand. 2010; 89(6):801–6. https://doi.org/10.3109/00016344100373954 PMID: 20504082

182. Scudiero R, Khoshnood B, Pryde PG, Lee KS, Wall S, Mittendorf R. Perinatal death and tocolytic magnesium sulfate. Obstet Gynecol. 2000; 96(2):178–82. https://doi.org/10.1016/s0029-7844(00)00893-0 PMID: 10908759

183. Shamsuddin L, Nahar K, Nasrin B, Nahar S, Tamanna S, Kabir RM, et al. Use of parenteral magnesium sulphate in eclampsia and severe pre-eclampsia cases in a rural set up of Bangladesh. Bangladesh Med Res Councl Bull. 2005; 31(2):75–82. PMID: 16967813

184. Shalabi M, Mohamed A, Lemyre B, Aziz K, Faucher D, Shah PS, et al. Antenatal exposure to magnesium sulfate and spontaneous intestinal perforation and necrotizing enterocolitis in extremely preterm neonates. Am J Perinatol. 2017; 34(12):1227–33. https://doi.org/10.1055/s-0037-1603344 PMID: 28494498

185. Shokry M, Elsedfy GO, Bassiouny MM, Anmin M, Abozid H. Effects of antenatal magnesium sulfate therapy on cerebral and systemic hemodynamics in preterm newborns. Acta Obstet Gynecol Scand. 2010; 89(6):801–6. https://doi.org/10.3109/00016344100373954 PMID: 20504082

186. Shokry M, Elsedfy GO, Bassiouny MM, Anmin M, Abozid H. Effects of antenatal magnesium sulfate therapy on cerebral and systemic hemodynamics in preterm newborns. Acta Obstet Gynecol Scand. 2010; 89(6):801–6. https://doi.org/10.3109/00016344100373954 PMID: 20504082

187. Stetson BT, Buhimschi CS, Kellert BA, Hay K, Buhimschi IA, Maitre NL. Comparison of cerebral palsy severity between 2 eras of antenatal magnesium use. JAMA Pediatr. 2019; 173(2):188–90. https://doi. org/10.1001/jamapediatrics.2018.3827 PMID: 30508016

188. Stockley EL, Ting JY, Kingdom JC, McDonald SD, Barrett JF, Synnes AR, et al. Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses. Am J Obstet Gynecol. 2018; 219(6):60661–8.

189. Suh B, Ko K, Bang J, Oh Y, Lee Y, Lee J, et al. Neonatal outcomes of premature infants who were delivered from mother with hypertensive disorders of pregnancy and effects of antihypertensive drugs and MgSO4. Korean J Perinatol. 2015; 26(3):190–9.

190. Teng RJ, Wu TJ, Sharma R, Garrison RD, Hudak ML. Early neonatal hypotension in premature infants born to preeclamptic mothers. J Perinatol. 2006; 26(8):471–5. https://doi.org/10.1088/sj.jp.7211558 PMID: 16775620
191. Verma RP, Chandra S, Niwas R, Komaroff E. Risk factors and clinical outcomes of pulmonary interstitial emphysema in extremely low birth weight infants. J Perinatol. 2006; 26(3):197–200. https://doi.org/10.1038/sj.jp.7211456 PMID: 16493434

192. Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O, et al. Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birth-weight infants. Arch Dis Child Fetal Neonatal Ed. 2001; 85(1):F13–7. https://doi.org/10.1136/fn.85.1.F13 PMID: 11420315

193. Weisz D, Shivananda S, Asztalos E, Yee W, Synnes A, Lee S, et al. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation. Arch Dis Child Fetal Neonatal Ed. 2015; 100(1):F59–65. https://doi.org/10.1136/archdischild-2013-305884 PMID: 25232002

194. Whitset A, Insel A, Desilva H, Bernstein B. Association of maternal antepartum management with mortality and morbidity of the extremely low birthweight (ELBW) neonate. Am J Obstet Gynecol. 2004; 191(6 Suppl):S75.

195. Whitten A, Ogunyemi D, Betcher K, Nowakowski A, Qu S. What factors predict prolonged neonatal length of stay in term babies? Int J Gynaecol Obstet. 2015; 131:E462–3.

196. Wiswell TE, Caddell JL, Graziani LJ, Kornhauser MS, Spitzer AR. Maternally-administered magnesium sulfate (MgSO4) decreases the incidence of severe necrotizing enterocolitis (NEC) in preterm infants: a prospective study. Pediatr Res. 1996; 39(4):1501.

197. Wutthigate P, Yangthara B, Siripattanapipong P, Kitsommart R. Correlation between maternal cumulative dose of intrapartum magnesium sulfate and cord blood magnesium level. Southeast Asian J Trop Med Public Health. 2017; 48(Suppl 2):256–63.

198. Yokoyama K, Takahashi N, Yada Y, Koike Y, Kawamata R, Uehara R, et al. Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010; 86(3):187–91. https://doi.org/10.1016/j.earlhumdev.2010.02.007 PMID: 20226604

199. Young BK, Weinstein HM. Effects of magnesium sulfate on toxemic patients in labor. Obstet Gynecol. 1977; 49(6):681–5. PMID: 865731

200. Ahmad S, Miller M, Slaughter S. Is there any evidence for fetal harm with prolonged used of magnesium sulfate in pregnant women? Pharmacoepidemiol Drug Saf. 2013; 22(1):141.

201. Amodio J, Berdon W, Abramson S, Stolar C. Microcolon of prematurity: a form of functional obstruction. AJR Am J Roentgenol. 1986; 146(2):239–44. https://doi.org/10.2214/a jr.146.2.239 PMID: 3484569

202. Cruz M, Doren A, Fernandez B, Antonio Salinas J, Urzua S, Lui Tapia J. Intoxicación neonatal por sulfato de magnesio: caso clínico. Rev Chil Pediatr. 2009; 80(3):261–6.

203. Cumming W, Thomas V. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. AJR Am J Roentgenol. 1989; 152(5):1071–2. https://doi.org/10.2214/ajr.152.5.1071 PMID: 2705341

204. Herschel M, Mittendorf R. Tocolytic magnesium sulfate toxicity and unexpected neonatal death. J Perinatol. 2001; 21(4):261–2. https://doi.org/10.1038/sj.jp.7200498 PMID: 11533846

205. Brady J. Magnesium intoxication in a premature infant. Pediatrics. 1967; 40(1):100–3. PMID: 6028888

206. Jashi R, Gorgadze N. Maternal medication part of infant mortality. J Matern Fetal Neonatal Med. 2014; 27:320–1.

207. Kaplan W, Haymond MW, McKay S, Karaviti LP. Osteopenic effects of MgSO4 in multiple pregnancies. J Pediatr Endocrinol Metab. 2006; 19(10):1225–30. https://doi.org/10.1515/jpem.2006.19.10.1225 PMID: 17172083

208. Kogan JM, Wedig KE, Whitsett JA, Schorry EK. Prolonged prenatal exposure to magnesium sulfate associated with bone abnormalities mimicking genetic bone disease. Am J Hum Genet. 2003; 73(5 Suppl):S90.

209. Krasna IH, Rosenfeld D, Salerno P. Is it necrotizing enterocolitis, microcolon of prematurity, or delayed meconium plug? A dilemma in the tiny premature infant. J Pediatr Surg. 1996; 31(6):855–8. https://doi.org/10.1016/S0022-3468(96)90153-0 PMID: 8783123

210. Kurtoğlu S, Caksen H, Poyrazoglu MH. Neonatal poisonings in middle Anatolia of Turkey: an analysis of 72 cases. J Toxicol Sci. 2000; 25(2):115–9. https://doi.org/10.2131/jts.25.115 PMID: 10845189

211. L’Hommedieu CS, Huber P, Rasch DK. Potentiation of magnesium-induced neuromuscular weakness by gentamicin. Crit Care Med. 1983; 11(1):55–6. https://doi.org/10.1097/00003324-198301000-00015 PMID: 6843809

212. Lamm C, Norton K, Murphy R, Wilkins I, Rabinowitz J. Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr. 1988; 113(6):1078–82. https://doi.org/10.1016/s0022-3476(88)80586-8 PMID: 3193315
213. Lipsitz P, English I. Hypermagnesemia in the newborn infant. Pediatrics. 1967; 40(5):856–62. PMID: 6075658

214. Malaeb S, Rassi A, Haddad M, Seoud M, Yunis K. Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of preterm labour. Pediatr Radiol. 2004; 34(384–6).

215. Rasch D, Richardson C. Effect of gentamicin on neuromuscular function (NMF) of a hypermagnesemic neonate. Pediatr Res. 1981; 15(4):499.

216. Sokal M, Koenigsberger M, Rose J, Berdon W, Santulli T. Neonatal hypermagnesemia and the meconium-plug syndrome. N Engl J Med. 1972; 286(1):823–5.

217. Tanaka K, Mori H, Sakamoto R, Matsumoto S, Mitsubuchi H, Nakamura K, et al. Early-onset neonatal hyperkalemia associated with maternal hypermagnesemia: a case report. BMC Pediatr. 2018; 15(1):55.

218. Teng R, Liu H, Tsou Yau K. Neonatal hypermagnesemia: report of one case. Acta Paediatr Sin. 1989; 30(5):333–6. PMID: 2637615

219. Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-Kantor E. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth. 2013; 13:34. https://doi.org/10.1186/1471-2393-13-34 PMID: 23383864

220. Duffy J, Hirsch M, Pealing L, Showell M, Khan KS, Ziebland S, et al. Inadequate safety reporting in pre-eclampsia trials: a systematic evaluation. Br J Obstet Gynaecol. 2018; 125(7):795–803.

221. McNamara HC, Crowther CA, Brown J. Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour. Cochrane Database Syst Rev. 2015;(12):CD011200. https://doi.org/10.1002/14651858.CD011200.pub2 PMID: 26662716

222. Gang BD. Antenatal magnesium sulphate is beneficial or harmful in very preterm and extremely preterm neonates: a new insight. J Matern Fetal Neonatal Med. 2019; 32(12):2084–90. https://doi.org/10.1080/14767058.2018.1424923 PMID: 29301419

223. Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med. 2016; 13(9):e1002127. https://doi.org/10.1371/journal.pmed.1002127 PMID: 27649528

224. Shea BJ, Reeves BC, Wells G, Thuku M, Harmel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4008. https://doi.org/10.1136/bmj.j4008 PMID: 28935701